


Synthesis of *gem*-Difluoromethylenated Polycyclic Cage Compounds

Chonticha Masusai,[†] Darunee Soorukram,[†] Chutima Kuhakarn,[†] Patoomratana Tuchinda,[†] Chaveng Pakawatchai,[‡] Saowanit Saithong,[‡] Vichai Reutrakul,[†] and Manat Pohmakotr^{*,†}

[†]Center of Excellence for Innovation in Chemistry (PERCH-CIC) and Department of Chemistry, Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand

[‡]Center of Excellence for Innovation in Chemistry (PERCH-CIC) and Department of Chemistry, Faculty of Science, Prince of Songkla University, Hat Yai, Songkla 90112, Thailand

Supporting Information



ABSTRACT: The synthesis of *gem*-difluoromethylenated polycyclic cage compounds, utilizing $\text{PhSCF}_2\text{SiMe}_3$ as a *gem*-difluoromethylene building block, is described. The fluoride-catalyzed nucleophilic addition of $\text{PhSCF}_2\text{SiMe}_3$ to both maleic anhydride–cyclopentadiene and maleic anhydride–cyclohexadiene adducts was accomplished with high stereoselectivity to provide the corresponding adducts that were treated with Grignard reagents, followed by acid-catalyzed lactonization to afford the corresponding γ -butyrolactones, each as a single isomer. These γ -butyrolactones underwent intramolecular radical cyclization to give the corresponding tetracyclic cage γ -butyrolactones, which were employed as precursors for the synthesis of *gem*-difluoromethylenated tetracyclic cage lactols or tetracyclic cage furans, upon treatment with Grignard reagents.

INTRODUCTION

Over the past decade, organofluorines have gained increasing interest due to their important roles in various fields, which include the pharmaceutical, agrochemical, and materials industries. Because of the special size of the fluorine atom, the high carbon–fluorine bond energy, and the special inductive and resonance effects caused by the fluorine atom, the presence of fluorine atoms in organic molecules was found to be beneficial to the physical and biological properties of fluorine-containing compounds.¹ Consequently, there has been tremendous interests in developing new and efficient methodologies to introduce fluorinated motifs into organic molecules.² Among those, convenient methods for the synthesis of *gem*-difluoromethylene-containing analogues of naturally occurring compounds received particular attention.³ We have recently reported the synthetic utilities of $\text{PhSCF}_2\text{SiMe}_3$ (**1**)⁴ as a useful *gem*-difluoromethylene building block for the syntheses of *gem*-difluoromethylenated 1-azabicyclic compounds,^{5,6} spiro- γ -butyrolactones,⁷ macrocyclic lactones,⁸ and cyclopentanols⁹ and as a difluoromethylating agent for the syntheses of difluoromethylketones,^{10,11} γ -difluoromethyl- γ -lactams,¹² and bicyclic ketones.¹³ The present work focuses on the synthesis of *gem*-difluoromethylenated polycyclic cage compounds, and to the best of our knowledge, the fluorinated cage compounds have rarely been reported in the literature.¹⁴ Carbocyclic and

heterocyclic cage compounds (Figure 1) have attracted particular attention from several research groups due to the challenges in their syntheses and for their chemical as well as biological activities.^{15,16} Their unique properties and chemical reactivities are associated with the rigid and highly compact structural frameworks. Cage compounds have also been employed as valuable synthetic intermediates in organic synthesis, especially for the synthesis of more complex cage and noncage polycyclic natural products.^{16v,z} Therefore, the incorporation of fluorinated motifs into polycyclic cage frameworks is of particular interest, since this class of compounds may be useful for the synthesis of other related highly substituted *gem*-difluoromethylenated polycyclic cage organic compounds and natural products. We report herein a general synthetic entry to *gem*-difluoromethylenated polycyclic cage compounds employing $\text{PhSCF}_2\text{SiMe}_3$ (**1**) as a useful *gem*-difluoromethylene building block.

RESULTS AND DISCUSSION

Noting our previous success in the fluoride-catalyzed nucleophilic addition of **1** and CF_3SiMe_3 to succinic anhydride,^{12,17} we reason that fluoride-catalyzed nucleophilic

Received: October 31, 2014

Published: January 13, 2015





Figure 1. Selected examples of the cage compounds.


Scheme 1. Synthetic Route to *gem*-Difluoromethylated Cage Compounds 8–13



addition of **1** to a maleic anhydride–cyclopentadiene adduct **2**¹⁸ and a maleic anhydride–cyclohexadiene adduct **3**¹⁸ should proceed with high stereoselectivity to produce the corresponding adducts **4** and **5** (Scheme 1). Stereoselective addition of Grignard reagents (R¹MgX) to **4** or **5** would provide **6** or **7**, which should serve as key compounds for the synthesis of *gem*-difluoromethylated cage γ -butyrolactone **8** (6,6-difluorooctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-ones) or **9** (7,7-difluorooctahydro-3,6-methanoindeno[1,7-*bc*]furan-2-(2*a*^{1*H*})-ones) through the readily formed *gem*-difluoromethylene radical upon the reductive cleavage of the PhS–CF₂ bond, followed by intramolecular radical cyclization using Bu₃SnH/AIBN. Finally, the cage γ -butyrolactones **8** and **9** would be transformed to the corresponding polycyclic cage compounds **10** (6,6-difluorooctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-ols) and **11** (7,7-difluorodecahydro-3,6-methanoindeno[1,7-*bc*]furan-2-ols) as well as **12** (6,6-difluorooctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furans) and **13** (7,7-difluorooctahydro-3,6-methanoindeno[1,7-*bc*]furans), respectively, upon treatment with Grignard reagents (R²MgX).

Fluoride-Catalyzed Nucleophilic Addition of 1 to Anhydrides 2 and 3. Optimization studies on fluoride-catalyzed nucleophilic addition of **1** to a maleic anhydride–cyclopentadiene adduct **2** were conducted (Table 1). Treatment of **1** (2 equiv) with **2** (1 equiv) in THF in the presence of 10 mol% of tetrabutylammonium difluorotriphenylsilicate (TBAT) at –10 °C for 5 h followed by quenching with water provided **4** (83% yield) along with **4A** (9% yield), each as a single isomer (Table 1, entry 1). The relative stereochemistries of **4** and **4A** were determined by X-ray crystallography (see the Supporting Information). Efforts to perform the reaction under other reaction conditions led to inferior results (Table 1). The reaction carried out at –78 °C

Table 1. Fluoride-Catalyzed Nucleophilic Addition of **1** to Anhydrides **2** and **3**




entry	substrate	conditions ^a	4 or 5 (%) ^{b,c}	4A (%) ^{b,c}
1	2	–10 °C, 5 h	4 (83)	9
2	2	–78 °C, 6 h	4 (62)	2
3	2	0 °C, 3 h	4 (50)	19
4	2	–10 °C to rt, 5 h	4 (10)	51
5	2	–10 °C to rt, 15 h	4 (13)	55
6	3	–10 °C, 5 h	5 (91)	

^aTwo equivalents of **1** was employed. ^bIsolated yield. ^cA single isomer of the product was obtained.


for 6 h gave lower yields of both **4** (62% yield) and **4A** (2% yield) (Table 1, entry 2). A dramatic decrease in the yields of **4** and a significant quantity of **4A** were observed when the reaction was carried out either at a higher temperature (0 °C to room temperature) or with an extended reaction time (Table 1, entries 3–5). Under the optimized reaction conditions as employed for compound **2** (Table 1, entry 1), compound **3** gave the expected adduct **5** in 91% yield as a single isomer, without the observation of its corresponding competing ring-opened product (Table 1, entry 6). The observed high stereoselectivity for the formation of compounds **4** and **5** could be reasoned by the nucleophile (“PhSCF₂–”) preferentially attacking the carbonyl group of the anhydride from the sterically less hindered convex side of **2** or **3**, leading to a

Scheme 2. Proposed Mechanism for the Formation of 4, 5, and 4A



trimethylsilyl ether **B** (Scheme 2). Simple hydrolysis of the trimethylsilyl ether **B** led to adducts **4** and **5**, each as a single isomer. Compound **4A** resulted from a fluoride-catalyzed ring-opening of the intermediate trimethylsilyl ether **B** to yield keto-carboxylate **C** followed by epimerization. The α -proton next to the phenylsulfanyldifluoromethyl carbonyl of the keto-carboxylate **C** should be highly acidic. Thus, under the reaction conditions, **C** underwent epimerization possibly via enolization by the fluoride-catalyzed α -proton abstraction and protonation process to yield the thermodynamically more stable isomer **4A**.


Preparation of *gem*-Difluoromethylenated γ -Butyrolactones **6 and **7**.** Having the key adducts **4** and **5** in hand, we then carried out the reactions of **4** and **5** with both Grignard reagents and reducing reagents. Initially, treatment of **4** with methylmagnesium chloride (5 equiv) afforded the corresponding γ -butyrolactone **6a** as a single isomer in 89% yield (Table 2, entry 1). The reactions of **4** and **5** with an array of Grignard reagents and reducing reagents, as listed in Table 2, were performed, and the results are also summarized in Table 2. It was found that **4** smoothly reacted with various Grignard reagents to provide the corresponding γ -butyrolactones **6b–g** in moderate to good yields (Table 2, entries 1–7). The reactions of **4** with both NaBH₄ and NaCNBH₃ afforded **6h** in high yields (Table 2, entries 8 and 9). It should be noted that the reaction of **4** with isopropylmagnesium chloride gave the expected product **6d** along with the reduction product **6h** in 56 and 30% yields, respectively (Table 2, entry 4). Although leading to poor results with isopropylmagnesium chloride, the reactions of **5** with other Grignard reagents provided the corresponding γ -butyrolactones **7a–c** and **7e–g** in high yields (Table 2, entries 10–12 and 14–16). Finally, the reaction of **5** with NaBH₄ in MeOH gave **7h** in 83% yield (Table 2, entry 17). It is worth noting that the reaction of **5** with ethylmagnesium chloride yielded the expected product **7b** in 75% yield, together with a separable diastereomeric mixture of **7h** and **7h'** in 7% and 9% yields, respectively (Table 2, entry 11). Compound **7h'** is probably a diastereomer of **7h**, which can be confirmed by NOE experiments (see the Supporting Information). The reaction of **5** with isopropylmagnesium chloride gave the expected product **7d** (21% yield) along with the reduction products **7h** (43% yield) and **7h'** (27% yield) (Table 2, entry 13). A transition state for the stereoselective nucleophilic addition of R¹MgX to **4** or **5** was proposed as

Table 2. Preparation of *gem*-Difluoromethylenated γ -Butyrolactones **6** and **7**

entry	4 or 5	reagent	R ¹	product 6 or 7 (% yield) ^{a,b}
1	4	CH ₃ MgCl	CH ₃	6a (89)
2	4	CH ₃ CH ₂ MgCl	CH ₃ CH ₂	6b (81)
3	4	CH ₃ (CH ₂) ₃ MgCl	CH ₃ (CH ₂) ₃	6c (87)
4	4	(CH ₃) ₂ CHMgCl	(CH ₃) ₂ CH	6d (56), 6h (30)
5	4	CH ₂ =CHMgCl	CH ₂ =CH	6e (89)
6	4	C ₆ H ₅ MgCl	C ₆ H ₅	6f (95)
7	4	4-MeOC ₆ H ₄ MgBr	4-MeOC ₆ H ₄	6g (69)
8	4	NaBH ₄	H	6h (85)
9	4	NaCNBH ₃	H	6h (90)
10	5	CH ₃ MgCl	CH ₃	7a (94)
11	5	CH ₃ CH ₂ MgCl	CH ₃ CH ₂	7b (75), 7h (7), 7h' (9) ^c
12	5	CH ₃ (CH ₂) ₃ MgCl	CH ₃ (CH ₂) ₃	7c (79), 7h' (3) ^c
13	5	(CH ₃) ₂ CHMgCl	(CH ₃) ₂ CH	7d (21), 7h (43), 7h' (27) ^c
14	5	CH ₂ =CHMgCl	CH ₂ =CH	7e (86)
15	5	C ₆ H ₅ MgCl	C ₆ H ₅	7f (91)
16	5	4-MeOC ₆ H ₄ MgBr	4-MeOC ₆ H ₄	7g (61)
17	5	NaBH ₄	H	7h (83)

^aIsolated yield by preparative thin-layer chromatography (SiO₂). ^bThe relative stereochemistry was proposed as shown in Scheme 3. ^cCompound **7h'** is probably a diastereomer of **7h**, which can be confirmed by NOE experiments (see the Supporting Information).

shown in Scheme 3.¹⁷ Proton abstraction of **4** or **5**, followed by ring-opening, led to the formation of **D** (Z = CH₂ or CH₂CH₂). Next, **D** was attacked either by R¹MgX or a hydride from the less hindered convex side to yield, after acid-catalyzed lactonization, the product **6** or **7**, each as a single isomer. Although it cannot be established at this stage, the relative stereochemistries of **6** and **7** are believed to possess the *gem*-difluorophenylsulfanylmethyl group (PhSCF₂) located on the

Scheme 3. Proposed Stereoselective Addition of R¹MgX and Hydride to 4 or 5

concave side of the molecules as depicted in Table 2 and Scheme 3. Compounds 6 and 7 whose relative stereochemistries are as shown in Table 2 and Scheme 3 should be capable of undergoing intramolecular radical cyclization upon the reductive cleavage of the phenylsulfanyl group. Thus, the formation of *gem*-difluoromethylenated cage γ -butyrolactones 8 and 9 should confirm the relative stereochemistries of their corresponding starting compounds 6 and 7, respectively.

Preparation of *gem*-Difluoromethylenated Cage γ -Butyrolactones 8 and 9. Having been successfully prepared, the *gem*-difluoromethylenated γ -butyrolactones 6 and 7 were next subjected to intramolecular radical cyclization mediated by Bu₃SnH/AIBN in refluxing toluene for overnight (15 h) (Table 3).¹⁹ It was found that in all cases the *gem*-difluoromethylenated γ -butyrolactones 6 and 7 readily underwent the reaction to furnish the corresponding *gem*-difluoromethylenated cage compounds 8a–g and 9a–h in good to excellent yields (76–99% yields), each as a single isomer. The results are summarized in Table 3. The obtained results fully confirmed

Table 3. Preparation of *gem*-Difluoromethylenated Cage γ -Butyrolactones 8 and 9


entry	6 or 7	R ¹	product 8 or 9 (yield) ^{a,b}
1	6a	CH ₃	8a (96)
2	6b	CH ₃ CH ₂	8b (88)
3	6c	CH ₃ (CH ₂) ₃	8c (85)
4	6e	CH ₂ =CH	8d (87)
5	6f	C ₆ H ₅	8e (91)
6	6g	4-MeOC ₆ H ₄	8f (76)
7	6h	H	8g (94)
8	7a	CH ₃	9a (89)
9	7b	CH ₃ CH ₂	9b (89)
10	7c	CH ₃ (CH ₂) ₃	9c (87)
11	7d	(CH ₃) ₂ CH	9d (99)
12	7e	CH ₂ =CH	9e (94)
13	7f	C ₆ H ₅	9f (97)
14	7g	4-MeOC ₆ H ₄	9g (89)
15	7h	H	9h (87)

^aIsolated yield by column chromatography (SiO₂) or preparative thin-layer chromatography (SiO₂). ^bA single isomer of the product was obtained.

the relative stereochemistries of the *gem*-difluoromethylenated γ -butyrolactones 6 and 7 (Table 2 and Scheme 3).



Preparation of *gem*-Difluoromethylenated Polycyclic Cage Compounds 10–13. Having established an entry to *gem*-difluoromethylenated cage compounds 8 and 9, we next demonstrated the synthetic utility of the method for the synthesis of an array of structurally different substituted *gem*-difluoromethylenated cage compounds. Thus, the reactions of 8 and 9 with various Grignard reagents were investigated. Primarily, treatment of 8e with an excess quantity of methylmagnesium chloride (5 equiv) in THF at 0 °C to room temperature for 1 h followed by an acidic workup (10% HCl) provided the cage lactol 10a, in a highly stereoselective manner, in 88% yield as a single isomer after chromatography (Table 4, entry 1). Under similar conditions, the reaction of 8f with methylmagnesium chloride gave a single isomer of the expected cage lactol 10b in 94% yield (Table 4, entry 2). Similarly, the reactions of 9a, 9c, 9f, 9g, and 9h with the Grignard reagents, as indicated in Table 4 (entries 3–11), also proceeded with high stereoselectivity to furnish moderate to good yields (67–91%) of the corresponding cage lactols 11a–i. The cage lactols 11a, 11b, 11c, 11e, 11f, and 11h were each obtained as a single isomer (Table 4, entries 3, 4, 5, 7, 8, and 10) while cage lactols 11d, 11g, and 11i were obtained as a mixture of isomers (¹⁹F NMR analysis) (Table 4, entries 6, 9, and 11). The relative stereochemistry of 11a was determined by X-ray crystallography (see the Supporting Information). Thus, the relative stereochemistries of 10a,b, 11b,c, 11e,f, 11h, and the major isomers of 11d, 11g, and 11i were assigned on the same basis of that of 11a.

It is anticipated that the reaction of *gem*-difluoromethylenated cage γ -butyrolactones 8 and 9 with Grignard reagents, at higher reaction temperature, should provide the *gem*-difluoromethylenated cage furan derivatives 12 and 13. Thus, compound 8a was treated with phenylmagnesium chloride, in refluxing THF, for 15 h followed by an acidic workup (10% HCl). Without chromatographic purification, the crude mixture was treated with a catalytic amount of *p*-TsOH in refluxing dichloromethane overnight (15 h) (Scheme 4). As expected, the corresponding *gem*-difluoromethylenated cage furan 12a was obtained in 59% yield along with keto-alcohol 14a (6% yield) and an unexpected *gem*-difluoromethylenated cage lactol 16a (26% yield) (Scheme 4). Under similar reaction conditions, the reaction of *gem*-difluoromethylenated cage lactone 9h with phenylmagnesium chloride yielded the *gem*-difluoromethylenated cage furan 13a, keto-alcohol 15a, and a rearranged product 17a in 31%, 38%, and 21% yields, respectively. The relative stereochemistries of the keto-alcohols 14a and 15a were assigned on the basis of NOESY experiments. The relative stereochemistry of 17a was confirmed by X-ray crystallography (see the Supporting Information).


Table 4. Preparation of *gem*-Difluoromethylenated Polycyclic Cage Compounds 10 and 11

entry	8 or 9 (R ¹)	R ² MgX	R ²	10 or 11 (% yield) ^a
1	8e (C ₆ H ₅)	CH ₃ MgCl	CH ₃	10a (88)
2	8f (4-MeOC ₆ H ₄)	CH ₃ MgCl	CH ₃	10b (94)
3	9a (CH ₃)	C ₆ H ₅ MgCl	C ₆ H ₅	11a (91)
4	9a (CH ₃)	2,4-(MeO) ₂ C ₆ H ₃ MgBr	2,4-(MeO) ₂ C ₆ H ₃	11b (80)
5	9c (CH ₃ (CH ₂) ₃)	C ₆ H ₅ MgCl	C ₆ H ₅	11c (69)
6	9f (C ₆ H ₅)	CH ₃ MgCl	CH ₃	11d (77) (97:3) ^b
7	9f (C ₆ H ₅)	4-MeOC ₆ H ₄ MgBr	4-MeOC ₆ H ₄	11e (75)
8	9f (C ₆ H ₅)	2,4-(MeO) ₂ C ₆ H ₃ MgBr	2,4-(MeO) ₂ C ₆ H ₃	11f (67)
9	9g (4-MeOC ₆ H ₄)	CH ₃ CH ₂ MgCl	CH ₃ CH ₂	11g (85) (92:8) ^b
10	9g (4-MeOC ₆ H ₄)	C ₆ H ₅ MgCl	C ₆ H ₅	11h (68)
11	9h (H)	CH ₃ (CH ₂) ₃ MgCl	CH ₃ (CH ₂) ₃	11i (69) (99:1) ^b

^aIsolated yield by column or preparative thin-layer chromatography (SiO₂). ^bThe diastereomeric ratio was determined by ¹⁹F NMR.

Scheme 4. Preparation of *gem*-Difluoromethylenated Polycyclic Cage Compounds 12–17Scheme 5. Proposed Nucleophilic Addition of R²MgX to 8 or 9 Leading to Compounds 10–15

Scheme 6. A Plausible Mechanism for the Formation of the Rearranged Products 16a and 17a



Thus, the relative stereochemistry of **16a** was also assigned on the basis of that of **17a**.

The formation and the resulting stereochemical outcome of compounds **10**–**15** can be rationalized by the addition of Grignard reagents to the carbonyl moiety of the *gem*-difluoromethylenated cage lactone **8** or **9** from the less hindered convex side in order to avoid the steric interaction leading to the alkoxide intermediates **D** (Scheme 5). At a low reaction temperature (0 °C, THF), the intermediates **D** underwent ring-opening to give the intermediates **E**, which yielded the *gem*-difluoromethylenated cage lactol **10** or **11** (from the corresponding cage lactone **8** or **9**, respectively), via the intermediates **F**, after acid-catalyzed cyclization. When the reaction was performed at a higher temperature and with a long reaction time (THF, reflux), the intermediates **E** were attacked by the second equivalent of the Grignard reagent leading to intermediates **G**, which upon acid treatment (*p*-TsOH, CH₂Cl₂, reflux), yielded the expected *gem*-difluoromethylenated cage furan **12** or **13**. The unreacted intermediates **E** underwent protonation followed by epimerization of α -carbon next to the carbonyl group to give the corresponding keto-alcohol **14** or **15**.

The formation of the unexpected rearranged products **16a** and **17a** during our investigation (Scheme 4) can be explained, as proposed in Scheme 6. It is possible that the intermediates **H**, derived from **G**, underwent chelation-mediated C–F bond cleavage to furnish fluoronium ion intermediates **I**. A stereoselective 1,2-alkyl (or hydride) migration of **I** gave the rearranged intermediates **J** which afforded the rearranged products **16a** and **17a** after treatment with acid.

CONCLUSIONS

In conclusion, we have demonstrated the synthetic utilities of PhSCF₂SiMe₃ (**1**) as a useful *gem*-difluoromethylene building block for the synthesis of *gem*-difluoromethylenated polycyclic cage compounds. The synthesis involved the sequential stereoselective fluoride-catalyzed nucleophilic addition of PhSCF₂SiMe₃ to maleic anhydride–cyclopentadiene and –cyclohexadiene adducts, the addition of the Grignard reagents or hydride reagents, and intramolecular radical cyclization. Our developed method may be useful for the synthesis of other related highly substituted polycyclic cage compounds contain-

ing a *gem*-difluoromethylene unit. Investigation in this area is now being undertaken.

EXPERIMENTAL SECTION

General Information. ¹H NMR spectra were recorded on 400 and 500 MHz spectrometers and are reported in ppm. Proton-decoupled ¹³C NMR spectra were recorded on 100 and 125 MHz spectrometers and are reported in ppm. ¹⁹F NMR spectra were recorded on 376 and 470 MHz spectrometers and are reported in ppm. Tetrahydrofuran (THF) was distilled from sodium–benzophenone ketyl. Dichloromethane (CH₂Cl₂) and toluene were distilled over calcium hydride and were stored over activated molecular sieves (4 Å). All glassware and syringes were oven-dried and kept in a desiccator before use. Preparative thin-layer chromatography plates were performed by using silica gel for preparative layer chromatography. Column chromatography was performed by using silica gel for column chromatography. Other common solvents [CH₂Cl₂, hexanes, ethyl acetate (EtOAc), methanol, and acetone] were distilled before use.

General Procedure for the Synthesis of *gem*-Difluoromethylenated Compounds **4 and **5**.** To a solution of PhSCF₂SiMe₃ (**1**, 2.32 g, 10.0 mmol) and **2** (821 mg, 5.0 mmol) in dry THF (15 mL) was added a solution of 10 mol % of TBAT (540 mg, 1.0 mmol) in dry THF (15 mL) at –10 °C under an argon atmosphere. The reaction mixture was stirred at –10 °C for 5 h and then quenched with water and extracted with EtOAc (3 × 30 mL). The combined organic phase was washed successively with water (30 mL) and brine (30 mL) and dried over anhydrous Na₂SO₄. After removal of the solvents, the crude product was purified by column chromatography (SiO₂, 5–30% EtOAc/hexanes) to give a single isomer of **4** (1.34 g, 83%) and a single isomer of **4A** (142 mg, 9%), each as a white solid.

(3*R**,3*aR**,4*S**,7*R**,7*aS**)-3-(Difluoro(phenylthio)methyl)-3-hydroxy-3*a*,4,7,7*a*-tetrahydro-4,7-methanoisobenzofuran-1(3*H*)-one (**4**). Less polar; mp 124–125 °C (CH₂Cl₂/hexanes); IR (KBr) 3338br, 3002m, 2970w, 1752br, 1443m, 1385m, 1196m, 1151m cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.54 (dt, *J* = 7.0, 1.6 Hz, 2H), 7.39 (tt, *J* = 7.4, 1.6 Hz, 1H), 7.32 (tt, *J* = 7.4, 1.5 Hz, 2H), 6.30 (dd, *J* = 5.6, 2.9 Hz, 1H), 6.12 (dd, *J* = 5.6, 2.9 Hz, 1H), 4.01 (s, 1H), 3.40 (dd, *J* = 9.1, 4.8 Hz, 1H), 3.32 (dd, *J* = 9.1, 3.9 Hz, 1H), 3.25–3.23 (m, 1H), 3.15 (br.s, 1H), 1.58 (dt, *J* = 8.8, 1.6 Hz, 1H), 1.42 (d, *J* = 8.8 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 173.9, 136.7, 136.7, 136.6, 133.9, 130.3, 129.2, 129.2, 127.4 (dd, *J* = 287.8, 287.3 Hz), 124.3, 103.7 (dd, *J* = 28.5, 28.5 Hz), 52.0, 50.0, 45.7, 45.4, 45.0; ¹⁹F NMR (470 MHz, CDCl₃): δ –89.8 (d, *J* = 210.5 Hz, 1F), –89.1 (d, *J* = 210.5 Hz, 1F); MS: *m/z* (% relative intensity) 324 (M⁺, 3), 258 (3), 165 (45), 160 (100), 149 (7), 110 (31), 99 (17), 77 (22), 67 (85); HRMS (ESI-TOF) calcd for C₁₆H₁₄F₂O₃SNa [M + Na]⁺ 347.0529, found 347.0528.

(1R*,2S*,3S*,4S*)-3-(2,2-Difluoro-2-(phenylthio)acetyl)bicyclo-[2.2.1]hept-5-ene-2-carboxylic acid (**4A**). More polar; mp 125–126 °C (CH₂Cl₂/hexanes); IR (KBr) 3448–2531br (COOH), 1737s (C=O), 1706s (C=O, acid), 1427m, 1314m, 1227m, 1069m, 1024m, 873s cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.59 (d, *J* = 7.2, 2H), 7.46 (tt, *J* = 7.4, 1.5 Hz, 1H), 7.38 (tt, *J* = 7.4, 1.5 Hz, 2H), 6.32 (dd, *J* = 5.6, 3.2 Hz, 1H), 6.20 (dd, *J* = 5.6, 2.8 Hz, 1H), 3.45 (dd, *J* = 4.2, 4.2 Hz, 1H), 3.33 (br.s, 1H), 3.22 (d, *J* = 4.6 Hz, 1H), 3.20 (br.s, 1H), 1.54 (d, *J* = 9.1 Hz, 1H), 1.44 (dd, *J* = 9.1, 1.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 197.1 (dd, *J* = 28.1, 28.1 Hz), 179.6, 138.3, 137.6, 137.6, 136.8, 131.4, 130.2, 130.2, 125.4, 123.8 (dd, *J* = 291.9, 288.3 Hz), 49.8, 48.7, 47.9, 47.2, 46.6; ¹⁹F NMR (470 MHz, CDCl₃): δ -84.4 (d, *J* = 217.8 Hz, 1F), -83.0 (d, *J* = 217.8 Hz, 1F); MS: *m/z* (% relative intensity) 324 (M⁺, 8), 258 (12), 165 (42), 159 (61), 137 (48), 109 (35), 99 (48), 77 (68), 67 (100); HRMS (ESI-TOF) calcd for C₁₆H₁₄F₂O₃SNa [M + Na]⁺ 347.0529, found 347.0527.

(3R*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3-hydroxy-3a,4,7,7a-tetrahydro-4,7-ethanoisobenzofuran-1(3H)-one (**5**). Under the same conditions as for **4**, a solution of **3** (713 mg, 4.0 mmol) and **1** (1.86 g, 8.0 mmol) in dry THF 10 mL was treated with a solution of 10 mol % of TBAT (432 mg, 0.8 mmol) in dry THF (10 mL) to provide a single isomer of **5** (1.24 g, 91%) as a white solid. Mp 124–125 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3191br, 2960w, 1788s, 1475w, 1190m, 1145m, 1042m, 970m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.67–7.60 (m, 2H), 7.50–7.37 (m, 3H), 6.40 (dd, *J* = 7.0, 7.0 Hz, 1H), 6.24 (dd, *J* = 7.4, 7.4 Hz, 1H), 4.06 (s, 1H), 3.18–3.12 (m, 1H), 3.04 (dd, *J* = 10.4, 3.3 Hz, 1H), 3.02–2.95 (m, 2H), 1.62–1.50 (m, 2H), 1.45–1.28 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 175.3, 136.8, 136.8, 134.3, 131.8, 130.3, 129.2, 129.2, 127.5 (dd, *J* = 288.2, 287.0 Hz), 124.4, 105.1 (dd, *J* = 29.0, 29.0 Hz), 47.5, 43.2, 31.7, 29.6, 24.1, 22.6; ¹⁹F NMR (376 MHz, CDCl₃): δ -90.1 (d, *J* = 210.9 Hz, 1F), -89.4 (d, *J* = 210.9 Hz, 1F); MS: *m/z* (% relative intensity) 338 (M⁺, 3), 179 (63), 160 (49), 159 (16), 109 (21), 77 (100); HRMS (ESI-TOF) calcd for C₁₇H₁₆F₂O₃SNa [M + Na]⁺ 361.0686, found 361.0681.

General Procedure for the Synthesis of gem-Difluoromethylene- γ -Butyrolactones **6 and **7**.** *General Procedure A.* A solution of **4** or **5** (0.5 mmol) in dry THF (15 mL) was treated with a THF solution of alkyl- or arylmagnesium chloride (1.6–3.0 M in THF, 2.5 mmol) at -78 or 0 °C under an argon atmosphere. After stirring at -78 °C for 1 h, or at 0 °C for 40 min, 10% HCl (2 mL) was added at -78 °C or at 0 °C. The aqueous phase was extracted with EtOAc (4 × 10 mL). The combined organic phase was washed with brine (20 mL) and dried over anhydrous Na₂SO₄. After removal of the solvents, the crude product was treated with a catalytic amount of *p*-TsOH in dry CH₂Cl₂ (12 mL) under reflux overnight (15 h). The reaction was quenched with saturated NaHCO₃ and extracted with CH₂Cl₂ (3 × 10 mL). The combined organic phase was washed with brine (10 mL) and dried over anhydrous Na₂SO₄. After removal of the solvents, the crude product was purified by column chromatography (SiO₂) or preparative thin-layer chromatography (SiO₂).

General Procedure B. A solution of alkyl- or aryl bromide (5.0 mmol) in dry THF (3 mL) was added dropwise into a suspension of Mg (turning) (200 mg, 10.0 mmol) in dry THF (2 mL) under an argon atmosphere at room temperature. After stirring for 2 h, a solution of freshly prepared Grignard reagent was transferred dropwise to a mixture solution of **4** or **5** (1.0 mmol) in dry THF (3 mL) via a cannula at -78 or 0 °C under an argon atmosphere, and the resulting mixture was stirred for 1 h. The reaction mixture was quenched with 10% HCl (5 mL) at -78 or 0 °C and extracted with EtOAc (4 × 10 mL). The combined organic phase was washed with brine (20 mL) and dried over anhydrous Na₂SO₄. After removal of the solvents, the crude product was treated with a catalytic amount of *p*-TsOH in dry CH₂Cl₂ (20 mL) under reflux overnight (15 h). The reaction was quenched with saturated NaHCO₃ and extracted with CH₂Cl₂ (3 × 15 mL). The combined organic phase was washed with brine (20 mL) and dried over anhydrous Na₂SO₄. After removal of the solvent, the crude product was purified by column

chromatography (SiO₂) or preparative thin-layer chromatography (SiO₂).

(3S*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3-methyl-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6a**). According to the general procedure A, the reaction of **4** (163 mg, 0.5 mmol) with methylmagnesium chloride (3.0 M in THF, 0.83 mL, 2.5 mmol) at 0 °C followed by lactonization gave **6a** (143 mg, 89%) as a white solid after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). Mp 105–106 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3028w, 2996w, 2948w, 1777s, 1442w, 1385w, 1247w, 1159m, 1095m, 957m cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.58–7.56 (m, 2H), 7.41–7.38 (m, 1H), 7.36–7.32 (m, 2H), 6.15 (dd, *J* = 5.7, 3.0 Hz, 1H), 6.13–6.04 (m, 1H), 3.45 (dd, *J* = 8.4, 5.2 Hz, 1H), 3.27 (br.s, 1H), 3.18–3.15 (m, 1H), 2.82 (dd, *J* = 8.5, 3.3 Hz, 1H), 1.62 (dt, *J* = 8.6, 1.7 Hz, 1H), 1.57 (s, 3H), 1.38 (d, *J* = 8.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 175.2, 136.9, 136.9, 135.4 (dd, *J* = 10.9, 7.4 Hz), 130.2, 129.1, 129.1, 129.1, 128.1 (dd, *J* = 288.4, 282.8 Hz), 124.9, 85.3 (dd, *J* = 27.3, 21.6 Hz), 53.6, 50.1, 48.2, 45.8, 43.9, 27.5; ¹⁹F NMR (470 MHz, CDCl₃): δ -82.0 (dd, *J* = 204.8, 4.9 Hz, 1F), -79.4 (dd, *J* = 204.8, 5.2 Hz, 1F); MS: *m/z* (% relative intensity) 322 (M⁺, 30), 257 (34), 159 (100), 110 (26), 77 (28); HRMS (ESI-TOF) calcd for C₁₇H₁₆F₂O₂SNa [M + Na]⁺ 345.0758, found 345.0737.

(3S*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3-methyl-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6b**). According to the general procedure A, the reaction of **4** (163 mg, 0.5 mmol) with ethylmagnesium chloride (2.0 M in THF, 1.25 mL, 2.5 mmol) at 0 °C followed by lactonization gave **6b** (136 mg, 81%) as a white solid after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). Mp 77–78 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2994w, 2948w, 1774s, 1475w, 1244m, 1157m, 980w cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.58–7.56 (m, 2H), 7.42–7.38 (m, 1H), 7.36–7.32 (m, 2H), 6.17–6.04 (m, 2H), 3.40 (dd, *J* = 8.6, 5.2 Hz, 1H), 3.33–3.26 (br, 1H), 3.17–3.10 (br, 1H), 2.85 (dd, *J* = 8.6, 3.2 Hz, 1H), 2.03–1.87 (m, 2H), 1.63 (d, *J* = 8.5 Hz, 1H), 1.40 (d, *J* = 8.5 Hz, 1H), 1.03 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 175.5, 136.9, 136.0 (dd, *J* = 7.9, 7.9 Hz), 136.0 (dd, *J* = 7.9, 7.9 Hz), 134.9, 130.2, 129.1, 129.1, 128.5 (dd, *J* = 290.0, 284.4 Hz), 125.1, 87.5 (dd, *J* = 26.1, 19.9 Hz), 53.9, 49.1, 48.1, 46.2, 43.9, 33.1, 8.1; ¹⁹F NMR (470 MHz, CDCl₃): δ -78.4 (dd, *J* = 208.0, 4.2 Hz, 1F), -75.6 (dd, *J* = 208.0, 5.4 Hz, 1F); MS: *m/z* (% relative intensity) 336 (M⁺, 7), 271 (7), 159 (100), 110 (33), 77 (31); HRMS (ESI-TOF) calcd for C₁₈H₁₈F₂O₂SNa [M + Na]⁺ 359.0893, found 359.0890.

(3S*,3aR*,4S*,7R*,7aS*)-3-Butyl-3-(difluoro(phenylthio)methyl)-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6c**). According to the general procedure A, the reaction of **4** (163 mg, 0.5 mmol) with butylmagnesium chloride (2.0 M in THF, 1.25 mL, 2.5 mmol) at 0 °C followed by lactonization gave **6c** (158 mg, 87%) as a white solid after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). Mp 87–88 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2962m, 1773s, 1475w, 1442w, 1247w, 1180m, 1130m, 1029m, 963m cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.69–7.62 (m, 2H), 7.48 (tt, *J* = 7.4, 1.7 Hz, 1H), 7.43 (tt, *J* = 7.3, 1.7 Hz, 2H), 6.23 (dd, *J* = 5.7, 3.0 Hz, 1H), 6.20–6.14 (m, 1H), 3.49 (dd, *J* = 8.7, 5.2 Hz, 1H), 3.39 (s, 1H), 3.25–3.20 (m, 1H), 2.95 (dd, *J* = 8.7, 3.3 Hz, 1H), 2.05–1.91 (m, 2H), 1.71 (dt, *J* = 8.6, 1.6 Hz, 1H), 1.62–1.51 (m, 1H), 1.48 (d, *J* = 8.6 Hz, 1H), 1.45–1.35 (m, 3H), 0.98 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 175.5, 136.8, 136.8, 135.9 (dd, *J* = 7.9, 7.9 Hz), 134.8, 130.1, 129.0, 129.0, 128.4 (dd, *J* = 286.2, 284.6 Hz), 125.0, 87.3 (dd, *J* = 25.8, 20.1 Hz), 53.9, 49.1, 48.4, 46.1, 43.8, 40.0, 25.4, 23.0, 13.8; ¹⁹F NMR (470 MHz, CDCl₃): δ -78.7 (dd, *J* = 207.0, 5.5 Hz, 1F), -75.7 (dd, *J* = 207.0, 5.5 Hz, 1F); MS: *m/z* (% relative intensity) 365 (M⁺ + H, 7), 299 (9), 255 (4), 205 (6), 189 (13), 159 (100), 139 (13), 110 (23), 77 (39); HRMS (ESI-TOF) calcd for C₂₀H₂₂F₂O₂SNa [M + Na]⁺ 387.1206, found 387.1183.

(3S*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3-isopropyl-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6d**). According to the general procedure A, the reaction of **4** (118 mg, 0.36 mmol) with isopropylmagnesium chloride (2.0 M in THF, 0.90 mL, 1.8 mmol) at -0 °C followed by lactonization gave **6d** (71 mg, 56%) as a white solid together with the reduction product **6h** (33 mg,

30%) as a colorless viscous oil after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). **6h**: mp 140–141 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2997m, 1780s, 1475m, 1442m, 1238m, 1178m, 1118m, 1065m, 989m cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.57–7.55 (m, 2H), 7.41–7.37 (m, 1H), 7.34–7.31 (m, 2H), 6.12–6.08 (m, 2H), 3.32 (dd, *J* = 9.1, 5.1 Hz, 1H), 3.18 (br.s, 1H), 3.11 (br.s, 1H), 2.84 (dd, *J* = 9.1, 3.3 Hz, 1H), 2.34 (sept, *J* = 6.7 Hz, 1H), 1.61 (d, *J* = 8.5 Hz, 1H), 1.39 (d, *J* = 8.5 Hz, 1H), 1.17 (dd, *J* = 6.8, 3.6 Hz, 3H), 0.98 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 175.6, 137.1, 137.1, 136.7 (d, *J* = 12.8 Hz), 134.0 (d, *J* = 4.3 Hz), 130.1, 129.4 (dd, *J* = 292.4, 283.1 Hz), 128.9, 128.9, 125.5, 89.7 (dd, *J* = 29.9, 19.8 Hz), 54.6, 50.2, 46.4, 44.7, 43.9, 36.2, 17.8, 17.5 (d, *J* = 4.3 Hz); ¹⁹F NMR (470 MHz, CDCl₃): δ -72.7 (d, *J* = 213.9 Hz, 1F), -69.4 (dd, *J* = 213.9, 10.3 Hz, 1F); MS: *m/z* (% relative intensity) 351 (M⁺ + H, 50), 350 (M⁺, 32), 285 (24), 173 (23), 159 (100), 110 (24), 77 (37); HRMS (ESI-TOF) calcd for C₁₉H₂₀F₂O₂SNa [M + Na]⁺ 373.1050, found 373.1041.

(3S*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3-vinyl-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6e**). According to the general procedure A, the reaction of **4** (163 mg, 0.5 mmol) with vinylmagnesium chloride (1.6 M in THF, 1.56 mL, 2.5 mmol) at 0 °C followed by lactonization gave **6e** (148 mg, 89%) as a white solid after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). Mp 127–128 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3029w, 2997w, 1780s, 1475w, 1118m, 1031w, 959w cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.56–7.53 (m, 2H), 7.40–7.37 (m, 1H), 7.34–7.31 (m, 2H), 6.16 (dd, *J* = 5.7, 3.0 Hz, 1H), 6.09–6.05 (m, 1H), 6.01 (dd, *J* = 17.0, 10.7 Hz, 1H), 5.42 (d, *J* = 17.0 Hz, 1H), 5.32 (d, *J* = 10.7 Hz, 1H), 3.26 (dd, *J* = 8.3, 5.2 Hz, 1H), 3.20 (s, 1H), 3.14–3.12 (m, 1H), 2.87 (dd, *J* = 8.3, 3.3 Hz, 1H), 1.62 (dt, *J* = 8.6, 1.6 Hz, 1H), 1.36 (d, *J* = 8.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 175.6, 136.8, 136.5, 135.7 (d, *J* = 5.0 Hz), 135.6, 130.1, 129.0, 129.0, 127.3 (dd, *J* = 290.1, 283.3 Hz), 125.4, 117.3, 86.2 (dd, *J* = 29.3, 24.6 Hz), 53.6, 48.8, 46.8, 45.6, 43.5; ¹⁹F NMR (470 MHz, CDCl₃): δ -80.5 (dd, *J* = 206.6, 1.4 Hz, 1F), -80.0 (dd, *J* = 206.6, 6.8 Hz, 1F); MS: *m/z* (% relative intensity) 335 (M⁺ + H, 88), 334 (M⁺, 65), 268 (24), 225 (14), 174 (12), 159 (100), 109 (14), 77 (24); HRMS (ESI-TOF) calcd for C₁₈H₁₆F₂O₂SNa [M + Na]⁺ 357.0737, found 357.0730.

(3R*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3-phenyl-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6f**). According to the general procedure A, the reaction of **4** (163 mg, 0.5 mmol) with phenylmagnesium chloride (2.0 M in THF, 1.25 mL, 2.5 mmol) at 0 °C followed by lactonization gave **6f** (183 mg, 95%) as a white solid after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). Mp 117–119 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2929w, 1781s, 1442w, 1118m, 1039m cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.55–7.52 (m, 2H), 7.42–7.37 (m, 2H), 7.36–7.29 (m, 4H), 7.26–7.23 (m, 2H), 6.18 (dd, *J* = 5.7, 2.9 Hz, 1H), 6.14–6.10 (m, 1H), 3.35 (s, 1H), 3.29 (dd, *J* = 8.0, 3.3 Hz, 1H), 3.10–3.05 (m, 2H), 1.62 (dt, *J* = 8.6, 1.5 Hz, 1H), 1.33 (d, *J* = 8.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 175.5, 139.9 (d, *J* = 3.9 Hz), 136.7, 136.7, 135.9 (d, *J* = 11.9 Hz), 135.4 (d, *J* = 3.3 Hz), 129.8, 129.1, 128.8, 128.8, 128.5, 128.5, 128.4 (dd, *J* = 295.2, 281.4 Hz), 126.3, 126.3, 125.8 (d, *J* = 3.1 Hz), 87.4 (dd, *J* = 33.1, 22.1 Hz), 53.6, 52.3, 47.0, 46.2, 43.6; ¹⁹F NMR (470 MHz, CDCl₃): δ -78.6 (d, *J* = 208.4 Hz, 1F), -76.9 (dd, *J* = 208.4, 10.1 Hz, 1F); MS: *m/z* (% relative intensity) 385 (M⁺ + H, 18), 384 (M⁺, 12), 318 (4), 275 (21), 225 (14), 159 (100), 77 (20); HRMS (ESI-TOF) calcd for C₂₂H₁₈F₂O₂SNa [M + Na]⁺ 407.0893, found 407.0877.

(3R*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3-(4-methoxyphenyl)-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6g**). According to the general procedure B, the reaction of **4** (324 mg, 1.0 mmol) with 4-methoxyphenylmagnesium bromide at 0 °C followed by lactonization gave **6g** (286 mg, 69%) as a white solid after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). Mp 130–132 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3009m, 1780s, 1610s, 1513s, 1442m, 1307m, 1257s, 1182s, 1113s, 1037s, 966m cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.46–7.42 (m, 4H), 7.33 (dt, *J* = 7.4, 1.6 Hz, 1H), 7.28–7.25 (m, 2H), 6.87 (dt, *J* = 9.0, 2.7 Hz, 2H), 6.18 (dd, *J* = 5.7, 2.6 Hz, 1H), 6.13–6.11 (m, 1H), 3.77 (s, 3H),

3.34 (s, 1H), 3.27 (dd, *J* = 7.7, 3.2 Hz, 1H), 3.10–3.08 (m, 2H), 1.63 (dd, *J* = 8.6, 1.6 Hz, 1H), 1.34 (d, *J* = 8.6 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 175.6, 160.2, 136.7, 136.7, 135.9 (d, *J* = 11.8 Hz), 135.4 (d, *J* = 3.0 Hz), 131.7 (d, *J* = 3.8 Hz), 129.8, 128.9, 128.9, 128.7 (dd, *J* = 295.6, 281.0 Hz), 127.8, 127.8, 126.1 (d, *J* = 3.0 Hz), 113.9, 113.9, 87.2 (dd, *J* = 33.3, 22.5 Hz), 55.3, 53.7, 52.2, 47.2, 46.2, 43.6; ¹⁹F NMR (470 MHz, CDCl₃): δ -78.7 (d, *J* = 207.7 Hz, 1F), -77.1 (dd, *J* = 207.7, 9.4 Hz, 1F); MS: *m/z* (% relative intensity) 414 (M⁺, 0.7), 305 (0.6), 255 (14), 189 (100), 161 (22), 133 (12), 77 (9); HRMS (ESI-TOF) calcd for C₂₃H₂₀F₂O₃SNa [M + Na]⁺ 437.0999, found 437.0978.

(3S*,3aR*,4S*,7R*,7aS*)-3-(Difluoro(phenylthio)methyl)-3a,4,7,7a-tetrahydro-4,7-methanoisobenzofuran-1(3H)-one (**6h**). Method A. To a solution of **4** (324 mg, 1.0 mmol) in methanol (2 mL) was added NaBH₄ (187 mg, 5.0 mmol) at 0 °C. After stirring at 0 °C for 2 h, the reaction mixture was quenched with 10% HCl (1 mL) and then diluted with water (2 mL) and extracted with EtOAc (4 × 5 mL). The combined organic phase was washed successively with water (10 mL) and brine (10 mL) and dried over anhydrous Na₂SO₄. After removal of the solvents, the crude product was treated with *p*-TsOH in CH₂Cl₂ (20 mL) under reflux for overnight (15 h) and then quenched with saturated NaHCO₃ and purified by preparative layer chromatography (SiO₂, 30% EtOAc/hexanes) to give **6h** (263 mg, 85%) as a colorless viscous oil.

Method B. To a solution of **4** (163 mg, 0.5 mmol) in acetic acid (3 mL) and a catalytic amount of trifluoroacetic anhydride (TFA) was added NaCNBH₃ (330 mg, 1.5 mmol) at 0 °C. After stirring at reflux for overnight (15 h), the reaction was quenched with 10% NaOH, diluted with water (5 mL), and extracted with CH₂Cl₂ (4 × 5 mL). The combined organic phase was washed with brine (10 mL) and dried over anhydrous Na₂SO₄. After removal of the solvent, the crude product was purified by preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes) to give **6h** (139 mg, 90%) as colorless viscous oil. IR (CHCl₃) 2980w, 1760s, 1411w, 1247w, 1173w, 987m, 934m cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 7.68–7.66 (m, 2H), 7.51–7.48 (m, 1H), 7.45–7.41 (m, 2H), 6.24–6.21 (m, 2H), 4.62 (ddd, *J* = 15.0, 10.4, 7.5 Hz, 1H), 3.45 (dd, *J* = 8.7, 5.1 Hz, 1H), 3.33 (br.s, 1H), 3.29–3.28 (m, 1H), 3.12 (ddd, *J* = 8.7, 7.5, 3.4 Hz, 1H), 1.70 (dt, *J* = 8.7, 1.7 Hz, 1H), 1.47 (d, *J* = 8.7 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 175.2, 136.5, 136.5, 135.5, 135.3 (dd, *J* = 6.0, 6.0 Hz), 130.3, 129.3, 129.3, 129.3, 125.9 (dd, *J* = 286.8, 279.4 Hz), 78.5 (dd, *J* = 33.0, 23.0 Hz), 53.4, 47.9, 44.9, 44.4, 42.0; ¹⁹F NMR (470 MHz, CDCl₃): δ -83.5 (dd, *J* = 213.2, 9.2 Hz, 1F), -80.2 (dd, *J* = 213.2, 15.0 Hz, 1F); MS: *m/z* (% relative intensity) 309 (M⁺ + H, 4), 308 (M⁺, 8), 242 (26), 214 (62), 159 (100), 148 (48), 110 (30), 66 (41); HRMS (ESI-TOF) calcd for C₁₆H₁₄F₂O₂SNa [M + Na]⁺ 331.0580, found 331.0603.

(3S*,4S*,7R*,7aS*)-3-Methyl-3a,4,7,7a-tetrahydro-4,7-ethanoisobenzofuran-1(3H)-one (**7a**). According to the general procedure A, the reaction of **5** (170 mg, 0.5 mmol) with methylmagnesium chloride (3.0 M in THF, 0.83 mL, 2.5 mmol) at 0 °C followed by lactonization gave **7a** (159 mg, 94%) as a white solid after preparative thin-layer chromatography (SiO₂, 20% EtOAc/hexanes). Mp 99–100 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2960w, 2943w, 2873w, 1774s, 1475w, 1442w, 1384w, 1271m, 1143m, 1057m, 962s cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.62–7.54 (m, 2H), 7.42–7.38 (m, 1H), 7.36–7.32 (m, 2H), 6.18–6.10 (m, 1H), 6.09–6.06 (m, 1H), 3.10–3.08 (br, 1H), 3.06–3.01 (m, 2H), 2.39 (dd, *J* = 8.5, 1.4 Hz, 1H), 1.53 (s, 3H), 1.49–1.41 (m, 2H), 1.38–1.28 (m, 1H), 1.27–1.14 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 176.0, 136.9, 136.9, 134.0 (dd, *J* = 4.0, 4.0 Hz), 131.0, 130.2, 129.2, 129.2, 128.5 (dd, *J* = 289.0, 283.0 Hz), 125.0, 87.0 (dd, *J* = 28.0, 22.0 Hz), 47.5, 46.5, 30.7, 30.6, 26.4, 26.4, 21.7; ¹⁹F NMR (376 MHz, CDCl₃): δ -83.3 (d, *J* = 207.0 Hz, 1F), -79.4 (dd, *J* = 207.0 Hz, 1F); MS: *m/z* (% relative intensity) 336 (M⁺, 39), 256 (2), 177 (5), 160 (100), 159 (17), 109 (40), 97 (11), 77 (87); HRMS (ESI-TOF) calcd for C₁₈H₁₈F₂O₂SNa [M + Na]⁺ 359.0893, found 359.0894.

(3S*,4S*,7R*,7aS*)-3-Ethyl-3a,4,7,7a-tetrahydro-4,7-ethanoisobenzofuran-1(3H)-one (**7b**). According to the general procedure A, the reaction of **5** (170 mg, 0.5 mmol) with ethylmagnesium chloride

(2.0 M in THF, 1.25 mL, 2.5 mmol) at 0 °C followed by lactonization gave **7b** (132 mg, 75%) as a white solid together with the reduction product **7h** (12 mg, 7%) and **7h'** (15 mg, 9%) after preparative thin-layer chromatography (SiO₂, 20% EtOAc/hexanes × 2). **7b**: mp 107–108 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2948w, 2873w, 1774s, 1474w, 1252w, 1187w, 1143m, 981m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.60–7.50 (m, 2H), 7.39–7.36 (m, 1H), 7.34–7.30 (m, 2H), 6.16–6.07 (m, 1H), 6.04 (dd, *J* = 7.8, 6.6 Hz, 1H), 3.13–3.04 (br, 1H), 3.02–2.96 (m, 1H), 2.95 (dd, *J* = 9.2, 4.2 Hz, 1H), 2.41 (dd, *J* = 9.2, 0.9 Hz, 1H), 1.99–1.80 (m, 2H), 1.50–1.38 (m, 2H), 1.35–1.13 (m, 2H), 0.98 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 176.5, 137.0, 137.0, 134.4 (dd, *J* = 5.0, 5.0 Hz), 130.4, 130.2, 129.1, 129.1, 128.8 (dd, *J* = 289.9, 284.9 Hz), 125.1, 139.2 (dd, *J* = 26.8, 20.2 Hz), 47.5, 45.3, 32.5, 30.7, 30.6, 26.5, 21.9, 8.0; ¹⁹F NMR (376 MHz, CDCl₃): δ -79.9 (d, *J* = 210.4 Hz, 1F), -75.1 (d, *J* = 210.4 Hz, 1F); MS: *m/z* (% relative intensity) 350 (M⁺, 25), 321 (10), 299 (23), 191 (8), 161 (13), 159 (13), 109 (42), 77 (100); HRMS (ESI-TOF) calcd for C₁₉H₂₀F₂O₂SNa [M + Na]⁺ 373.1050, found 373.1046.

(3*R**,4*S**,7*R**,7*aS**)-3-(Difluoro(phenylthio)methyl)-3*a*,4,7,7*a*-tetrahydro-4,7-ethanoisobenzofuran-1(3*H*)-one (**7h'**). White solid; mp 93–94 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3029w, 2957m, 2874w, 1784s, 1475m, 1442m, 1245m, 1166m, 1142m, 1063m, 991m, 979m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.60–7.50 (m, 2H), 7.41–7.36 (m, 1H), 7.35–7.28 (m, 2H), 6.29–6.25 (m, 1H), 6.16 (dd, *J* = 7.4, 7.0 Hz, 1H), 4.08 (ddd, *J* = 11.9, 8.9, 3.2 Hz, 1H), 3.02 (dd, *J* = 4.5, 1.5 Hz, 1H), 2.82–2.72 (m, 2H), 2.71 (dd, *J* = 4.5, 1.5 Hz, 1H), 1.56–1.47 (m, 2H), 1.32–1.20 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 177.4, 136.6, 136.6, 134.6, 132.3, 130.3, 129.3, 129.3, 127.4 (dd, *J* = 281.4, 281.4 Hz), 124.9, 83.1 (dd, *J* = 29.7, 26.8 Hz), 44.8, 39.6, 33.2, 31.8, 23.4, 23.1; ¹⁹F NMR (376 MHz, CDCl₃): δ -87.3 (dd, *J* = 215.7, 10.9 Hz, 1F), -85.4 (dd, *J* = 215.7, 8.5 Hz, 1F); MS: *m/z* (% relative intensity) 322 (M⁺, 73), 242 (2), 213 (2), 163 (53), 159 (15), 133 (7), 109 (20), 77 (100); HRMS (ESI-TOF) calcd for C₁₇H₁₆F₂O₂SNa [M + Na]⁺ 345.0737, found 345.0749.

(3*S**,4*S**,7*R**,7*aS**)-3-Butyl-3*a*,4,7,7*a*-tetrahydro-4,7-ethanoisobenzofuran-1(3*H*)-one (**7c**). According to the general procedure A, the reaction of **5** (170 mg, 0.5 mmol) with butylmagnesium chloride (2.0 M in THF, 1.25 mL, 2.5 mmol) at 0 °C followed by lactonization gave **7c** (150 mg, 79%) as a white solid together with **7h'** (5 mg, 3%) after preparative thin-layer chromatography (SiO₂, 20% EtOAc/hexanes). Compound **7c** was recrystallized from CH₂Cl₂/hexane. Mp 70–71 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2961s, 2874m, 1773s, 1474m, 1182m, 1143m, 1025m, 988m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.71–7.60 (m, 2H), 7.52–7.36 (m, 3H), 6.25–6.17 (m, 1H), 6.14 (dd, *J* = 7.7, 6.5 Hz, 1H), 3.22–3.14 (br, 1H), 3.13–3.08 (br, 1H), 3.06 (dd, *J* = 9.1, 4.2 Hz, 1H), 2.51 (br.d, *J* = 8.8 Hz, 1H), 2.00–1.86 (m, 2H), 1.60–1.45 (m, 3H), 1.44–1.22 (m, 5H), 0.97 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 176.3, 136.9, 136.9, 134.4 (dd, *J* = 5.0, 5.0 Hz), 130.4, 130.1, 129.1, 129.1, 128.8 (dd, *J* = 290.6, 284.2 Hz), 125.2, 89.0 (dd, *J* = 27.0, 20.2 Hz), 47.5, 45.8, 39.4, 30.8, 30.6, 26.5, 25.3, 23.1, 21.9, 13.9; ¹⁹F NMR (376 MHz, CDCl₃): δ -80.2 (d, *J* = 209.6 Hz, 1F), -75.4 (d, *J* = 209.6 Hz, 1F); MS: *m/z* (% relative intensity) 378 (M⁺, 26), 322 (15), 219 (17), 189 (4), 159 (17), 139 (15), 109 (40), 77 (100); HRMS (ESI-TOF) calcd for C₂₁H₂₄F₂O₂SNa [M + Na]⁺ 401.1363, found 401.1369.

(3*S**,4*S**,7*R**,7*aS**)-3-Isopropyl-3*a*,4,7,7*a*-tetrahydro-4,7-ethanoisobenzofuran-1(3*H*)-one (**7d**). According to the general procedure A, the reaction of **5** (339 mg, 1.0 mmol) with isopropylmagnesium chloride (2.0 M in THF, 2.50 mL, 5.0 mmol) at -78 °C followed by lactonization gave **7d** (78 mg, 21%) as a white solid together with **7h** (139 mg, 43%) and **7h'** (87 mg, 27%) after preparative thin-layer chromatography (SiO₂, 20% EtOAc/hexanes and then 5% EtOAc/hexanes × 5). **7d**: mp 159–161 °C (CH₂Cl₂/hexane); IR (CHCl₃) 2956m, 2873w, 1773s, 1475m, 1254m, 1179m, 1144m, 1034m, 988m, 905m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.60–7.53 (m, 2H), 7.40–7.37 (m, 1H), 7.34–7.30 (m, 2H), 6.09 (dd, *J* = 15.6, 8.3 Hz, 1H), 6.02 (dd, *J* = 8.3, 6.5 Hz, 1H), 3.01–2.90 (m, 2H), 2.86 (dd, *J* = 9.8, 4.1 Hz, 1H), 2.40 (d, *J* = 9.8 Hz, 1H), 2.34 (sept, *J* = 6.8 Hz, 1H), 1.49–1.37 (m, 2H), 1.33–1.15 (m, 2H), 1.11 (dd, *J* = 6.8, 4.4 Hz, 3H), 0.93 (d, *J* = 6.8, 4.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ

176.5, 137.2, 137.2, 134.9 (d, *J* = 9.7 Hz), 130.1, 129.5 (d, *J* = 3.7 Hz), 129.8 (dd, *J* = 292.5, 283.5 Hz), 129.0, 129.0, 125.5, 91.2 (dd, *J* = 29.0, 21.0 Hz), 48.8, 42.0, 36.0, 30.4, 26.5, 22.3, 17.7, 17.2, 17.2; ¹⁹F NMR (376 MHz, CDCl₃): δ -74.2 (d, *J* = 214.8 Hz, 1F), -70.7 (dd, *J* = 214.8, 6.9 Hz, 1F); MS: *m/z* (% relative intensity) 364 (M⁺, 14), 321 (22), 313 (54), 255 (9), 205 (8), 159 (25), 109 (51), 77 (100); HRMS (ESI-TOF) calcd for C₂₀H₂₂F₂O₂SNa [M + Na]⁺ 387.1206, found 387.1205.

(3*S**,4*S**,7*R**,7*aS**)-3-Vinyl-3*a*,4,7,7*a*-tetrahydro-4,7-ethanoisobenzofuran-1(3*H*)-one (**7e**). According to the general procedure A, the reaction of **5** (170 mg, 0.5 mmol) with vinylmagnesium chloride (1.6 M in THF, 1.56 mL, 2.5 mmol) at 0 °C followed by lactonization gave **7e** (149 mg, 86%) as a white solid after preparative thin-layer chromatography (SiO₂, 20% EtOAc/hexanes). Mp 117–118 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2959w, 2873w, 1781s, 1475w, 1252m, 1185m, 1116m, 1063m, 989m, 907m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.45–7.43 (m, 2H), 7.30–7.19 (m, 3H), 6.08–6.01 (m, 1H), 6.00 (dd, *J* = 13.2, 6.9 Hz, 1H), 5.86 (dd, *J* = 17.0, 10.7 Hz, 1H), 5.29 (d, *J* = 17.0 Hz, 1H), 5.20 (d, *J* = 10.7 Hz, 1H), 2.95–2.84 (m, 2H), 2.77 (dd, *J* = 8.8, 4.3 Hz, 1H), 2.36 (dd, *J* = 8.8, 1.3 Hz, 1H), 1.37–1.27 (m, 2H), 1.24–1.15 (m, 1H), 1.12–1.02 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 176.4, 136.9, 136.9, 135.9 (d, *J* = 2.1 Hz), 134.1 (d, *J* = 6.9 Hz), 131.2, 130.1, 127.6 (dd, *J* = 292.9, 281.5 Hz), 129.1, 129.1, 125.4, 117.2, 87.7 (dd, *J* = 30.3, 23.0 Hz), 46.4, 45.1, 30.6, 30.5, 26.5, 21.5; ¹⁹F NMR (376 MHz, CDCl₃): δ -81.9 (d, *J* = 208.1 Hz, 1F), -80.5 (d, *J* = 208.1 Hz, 1F); MS: *m/z* (% relative intensity) 348 (M⁺, 34), 271 (6), 189 (45), 159 (23), 109 (70), 77 (100); HRMS (ESI-TOF) calcd for C₁₉H₁₈F₂O₂SNa [M + Na]⁺ 371.0893, found 371.0896.

(3*R**,4*S**,7*R**,7*aS**)-3-Phenyl-3*a*,4,7,7*a*-tetrahydro-4,7-ethanoisobenzofuran-1(3*H*)-one (**7f**). According to the general procedure A, the reaction of **5** (339 mg, 1.0 mmol) with phenylmagnesium chloride (2.0 M in THF, 1.25 mL, 2.5 mmol) at 0 °C followed by lactonization gave **7f** (362 mg, 91%) as a white solid after preparative thin-layer chromatography (SiO₂, 20% EtOAc/hexanes). Mp 132–133 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2959w, 2873w, 1782s, 1474w, 1248w, 1171m, 1116m, 1042m, 1033m, 984m, 904m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.58–7.46 (m, 2H), 7.44–7.39 (m, 2H), 7.38–7.29 (m, 4H), 7.28–7.20 (m, 2H), 6.21 (dd, *J* = 13.6, 7.0 Hz, 1H), 6.12 (dd, *J* = 14.5, 7.0 Hz, 1H), 3.24–3.16 (m, 1H), 3.03–2.95 (m, 1H), 2.89 (dd, *J* = 8.7, 0.8 Hz, 1H), 2.68 (dd, *J* = 8.7, 4.3 Hz, 1H), 1.51–1.43 (m, 1H), 1.39–1.14 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 176.3, 139.5 (d, *J* = 3.5 Hz), 136.9, 136.9, 134.4 (d, *J* = 7.1 Hz), 131.1, 129.9, 129.2, 128.9, 128.9, 128.7 (dd, *J* = 292.9, 284.0 Hz), 128.6, 128.6, 126.4, 126.4, 125.9 (d, *J* = 3.0 Hz), 88.9 (dd, *J* = 32.0, 22.6 Hz), 50.3, 45.7, 31.1, 30.6, 26.8, 21.4; ¹⁹F NMR (376 MHz, CDCl₃): δ -80.3 (d, *J* = 209.6 Hz, 1F), -77.6 (d, *J* = 209.6 Hz, 1F); MS: *m/z* (% relative intensity) 398 (M⁺, 11), 239 (100), 159 (84), 109 (15), 77 (49); HRMS (ESI-TOF) calcd for C₂₃H₂₀F₂O₂SNa [M + Na]⁺ 421.1050, found 421.1055.

(3*R**,4*S**,7*R**,7*aS**)-3-(4-Methoxyphenyl)-3*a*,4,7,7*a*-tetrahydro-4,7-ethanoisobenzofuran-1(3*H*)-one (**7g**). According to the general procedure B, the reaction of **5** (170 mg, 0.5 mmol) with 4-methoxyphenylmagnesium bromide at 0 °C followed by lactonization gave **7g** (131 mg, 61%) as a white solid after preparative thin-layer chromatography (SiO₂, 30% EtOAc/hexanes). Mp 139–140 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2958w, 1781s, 1610m, 1513s, 1258m, 1182m, 1110m, 1036m, 983m, 906m, 810m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.44–7.37 (m, 4H), 7.33–7.28 (m, 1H), 7.27–7.20 (m, 2H), 6.88–6.82 (m, 2H), 6.18 (dd, *J* = 14.2, 7.0 Hz, 1H), 6.09 (dd, *J* = 14.2, 7.0 Hz, 1H), 3.74 (s, 3H), 3.20–3.12 (br, 1H), 3.01–2.94 (br, 1H), 2.85 (d, *J* = 8.6 Hz, 1H), 2.68 (dd, *J* = 8.6, 4.3 Hz, 1H), 1.51–1.42 (m, 1H), 1.38–1.13 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 176.4, 160.2, 136.8, 136.8, 134.4 (d, *J* = 6.9 Hz), 131.2 (d, *J* = 3.6 Hz), 131.1, 129.9, 128.9, 128.9, 128.8 (dd, *J* = 294.8, 280.5 Hz), 127.8, 127.8, 126.0 (d, *J* = 3.1 Hz), 113.9, 113.9, 88.8 (dd, *J* = 32.0, 22.6 Hz), 55.3, 50.1, 45.8, 31.1, 30.6, 28.8, 21.4; ¹⁹F NMR (376 MHz, CDCl₃): δ -80.5 (d, *J* = 207.6 Hz, 1F), -77.8 (d, *J* = 207.6 Hz, 1F); MS: *m/z* (% relative intensity) 429 (M⁺ + H, 0.4), 269 (100), 189

(77), 159 (1), 109 (7), 77 (23); HRMS (ESI-TOF) calcd for $C_{24}H_{22}F_3O_3SnNa$ $[M + Na]^+$ 451.1155, found 451.1157.

(3*S**,4*S**,7*R**,7*aS**)-3-(Difluoro(phenylthio)methyl)-3*a*,4,7,7*a*-tetrahydro-4,7-ethanoisobenzofuran-1(3*H*)-one (**7h**). According to method A for the synthesis of **6h**, a solution of **5** (170 mg, 0.5 mmol) in methanol (1 mL) was treated with $NaBH_4$ (94 mg, 2.5 mmol). The crude product was purified by preparative thin-layer chromatography (SiO_2 , 50% CH_2Cl_2 /hexanes) to give **7h** (134 mg, 83%) as a white solid. Mp 91–92 °C (CH_2Cl_2 /hexanes); IR ($CHCl_3$) 2959w, 2944w, 2874w, 1784s, 1475w, 1342w, 1242w, 1166m, 1145m, 1065w, 1053w, 979m, 968m cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 7.66–7.64 (m, 2H), 7.49–7.45 (m, 1H), 7.43–7.39 (m, 2H), 6.30–6.22 (m, 1H), 6.17 (dd, $J = 7.4, 7.0$, 1H), 4.53 (ddd, $J = 15.9, 8.9, 7.7$ Hz, 1H), 3.15–3.05 (m, 2H), 2.99 (dd, $J = 9.2, 4.2$ Hz, 1H), 2.73–2.69 (m, 1H), 1.58–1.47 (m, 2H), 1.46–1.20 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 176.2, 136.7, 136.7, 133.9 (dd, $J = 3.2, 3.2$ Hz), 131.5, 130.4, 129.4, 129.4, 126.2 (dd, $J = 285.7, 279.6$ Hz), 125.5, 79.8 (dd, $J = 33.2, 23.4$ Hz), 46.4, 39.7, 30.9, 29.6, 26.0, 21.7; ^{19}F NMR (376 MHz, $CDCl_3$): δ -84.3 (dd, $J = 216.0, 6.0$ Hz, 1F), -81.6 (dd, $J = 216.0, 12.8$ Hz, 1F); MS: m/z (% relative intensity) 323 ($M^+ + H$, 100), 322 (M^+ , 29), 243 (1), 159 (9), 133 (2); HRMS (ESI-TOF) calcd for $C_{17}H_{16}F_2O_3SnNa$ $[M + Na]^+$ 345.0737, found 345.0730.

Synthesis of gem-Difluoromethylenated Polycyclic Cage γ -Butyrolactones **8 and **9**. General Procedure C.** A degassed solution (5 mL) of Bu_3SnH (0.20 mL, 0.75 mmol) and AIBN (7 mg, 1 mol %) was added into a refluxing degassed toluene solution (7 mL) of **6** or **7** (0.5 mmol) under an argon atmosphere. After stirring at reflux for overnight (15 h), the crude product was purified by column chromatography (SiO_2) or preparative thin-layer chromatography (SiO_2).

(6*aS**)-6,6-Difluoro-6*a*-methyloctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-one (**8a**). According to the general procedure C, radical cyclization of **6a** (309 mg, 0.96 mmol) gave **8a** (197 mg, 96%) as a white solid after column chromatography (SiO_2 , hexanes) and then 5% EtOAc/hexanes). Mp 80–82 °C (CH_2Cl_2 /hexanes); IR ($CHCl_3$) 2988w, 2971w, 1777s, 1455w, 1344m, 1245s, 1194s, 1089s cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$): δ 3.03 (ddd, $J = 10.2, 4.5, 2.2$ Hz, 1H), 2.75–2.71 (m, 1H), 2.68–2.60 (m, 2H), 2.53–2.47 (m, 1H), 1.76–1.63 (m, 4H), 1.44 (d, $J = 4.4$ Hz, 3H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 175.9, 127.1 (dd, $J = 268.5, 245.8$ Hz), 89.2 (dd, $J = 31.8, 19.4$ Hz), 52.4 (d, $J = 3.4$ Hz), 51.2, 45.0 (dd, $J = 25.8, 21.1$ Hz), 42.3 (d, $J = 5.6$ Hz), 41.4, 39.9, 28.2 (d, $J = 9.5$ Hz), 19.0 (d, $J = 6.4$ Hz); ^{19}F NMR (470 MHz, $CDCl_3$): δ -119.2 (d, $J = 240.9$ Hz, 1F), -101.0 (d, $J = 240.9$ Hz, 1F); MS: m/z (% relative intensity) 215 ($M^+ + H$, 11), 214 (M^+ , 4), 196 (6), 170 (38), 149 (91), 147 (16), 121 (17), 97 (22), 91 (100), 77 (42); HRMS (ESI-TOF) calcd for $C_{11}H_{12}F_2O_2Na$ $[M + Na]^+$ 237.0703, found 237.0690.

(6*aS**)-6*a*-Ethyl-6,6-difluorooctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-one (**8b**). According to the general procedure C, radical cyclization of **6b** (65 mg, 0.2 mmol) gave **8b** (40 mg, 88%) as a white solid after column chromatography (SiO_2 , hexanes) and then 5% EtOAc/hexanes). Mp 66–67 °C (CH_2Cl_2 /hexanes); IR ($CHCl_3$) 2973m, 2886w, 1769s, 1464w, 1313w, 1291w, 1196m, 1096m, 988m cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$): δ 3.00 (ddd, $J = 10.2, 4.5, 2.2$ Hz, 1H), 2.77–2.74 (m, 1H), 2.67–2.59 (m, 2H), 2.52–2.46 (m, 1H), 1.99–1.87 (m, 1H), 1.75–1.63 (m, 5H), 0.97 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 176.2, 127.6 (dd, $J = 269.1, 246.3$ Hz), 91.5 (dd, $J = 30.5, 18.4$ Hz), 50.9, 50.4 (d, $J = 3.5$ Hz), 45.4 (dd, $J = 25.9, 21.4$ Hz), 42.2 (d, $J = 5.6$ Hz), 41.3, 39.9, 28.1 (d, $J = 9.4$ Hz), 25.8 (d, $J = 5.4$ Hz), 7.6; ^{19}F NMR (470 MHz, $CDCl_3$): δ -115.5 (d, $J = 242.1$ Hz, 1F), -103.3 (dd, $J = 242.1, 12.7$ Hz, 1F); MS: m/z (% relative intensity) 228 (M^+ , 10), 199 (13), 184 (27), 178 (20), 161 (10), 149 (85), 134 (23), 81 (79), 67 (86), 55 (100); HRMS (ESI-TOF) calcd for $C_{12}H_{14}F_2O_2Na$ $[M + Na]^+$ 251.0860, found 251.0839.

(6*aS**)-6*a*-Butyl-6,6-difluorooctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-one (**8c**). According to the general procedure C, radical cyclization of **6c** (229 mg, 0.63 mmol) gave **8c** (137 mg, 85%) as a white solid after column chromatography (SiO_2 , hexanes) and then 5% EtOAc/hexanes). Mp 58–59 °C (CH_2Cl_2 /

hexanes); IR ($CHCl_3$) 2962s, 2876w, 1769s, 1469w, 1457w, 1346w, 1313w, 1239m, 1196m, 1102m, 1093m, 995w cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$): δ 2.99 (ddd, $J = 10.3, 4.5, 2.1$ Hz, 1H), 2.77–2.74 (m, 1H), 2.63 (s, 2H), 2.51–2.46 (m, 1H), 1.94–1.82 (m, 1H), 1.74–1.55 (m, 5H), 1.50–1.38 (m, 1H), 1.37–1.21 (m, 3H), 0.85 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 176.2, 127.6 (dd, $J = 269.1, 246.5$ Hz), 91.2 (dd, $J = 30.4, 18.7$ Hz), 50.8, 50.7 (d, $J = 3.4$ Hz), 45.4 (dd, $J = 26.0, 21.2$ Hz), 42.2 (d, $J = 5.8$ Hz), 41.3, 39.9, 32.6 (d, $J = 4.6$ Hz), 28.1 (d, $J = 9.4$ Hz), 25.2, 22.9, 13.8; ^{19}F NMR (470 MHz, $CDCl_3$): δ -115.7 (d, $J = 241.6$ Hz, 1F), -102.9 (dd, $J = 241.6, 12.7$ Hz, 1F); MS: m/z (% relative intensity) 257 ($M^+ + H$, 87), 256 (9), 227 (100), 190 (16), 174 (58); HRMS (ESI-TOF) calcd for $C_{14}H_{18}F_2O_2Na$ $[M + Na]^+$ 279.1173, found 279.1164.

(6*aS**)-6,6-Difluoro-6*a*-vinyloctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-one (**8d**). According to the general procedure C, radical cyclization of **6e** (67 mg, 0.2 mmol) gave **8d** (39 mg, 87%) as a white solid after column chromatography (SiO_2 , hexanes) and then 5% EtOAc/hexanes) and preparative thin-layer chromatography (SiO_2 , 20% EtOAc/hexanes). Mp 95–96 °C (CH_2Cl_2 /hexanes); IR ($CHCl_3$) 3020m, 2970w, 1774s, 1342m, 1111m, 1008m cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 5.93 (ddd, $J = 17.2, 11.0, 3.7$ Hz, 1H), 5.49 (d, $J = 17.2$ Hz, 1H), 5.29 (d, $J = 11.0$ Hz, 1H), 3.04 (ddd, $J = 10.3, 4.4, 1.9$ Hz, 1H), 2.93–2.86 (m, 1H), 2.78–2.70 (br, 1H), 2.69–2.63 (br, 1H), 2.60–2.48 (m, 1H), 1.80–1.57 (m, 4H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 175.6, 131.4 (d, $J = 6.0$ Hz), 127.4 (dd, $J = 271.0, 246.0$ Hz), 117.3 (d, $J = 2.0$ Hz), 89.9 (dd, $J = 30.5, 19.5$ Hz), 51.6 (d, $J = 4.0$ Hz), 50.4, 45.2 (dd, $J = 25.0, 21.0$ Hz), 42.6 (d, $J = 6.0$ Hz), 41.3, 40.0, 28.1 (d, $J = 9.0$ Hz); ^{19}F NMR (376 MHz, $CDCl_3$): δ -117.4 (d, $J = 239.1$ Hz, 1F), -99.2 (dd, $J = 239.1, 11.3$ Hz, 1F); MS: m/z (% relative intensity) 227 ($M^+ + H$, 100), 226 (M^+ , 9), 159 (4), 107 (17); HRMS (ESI-TOF) calcd for $C_{12}H_{12}F_2O_2Na$ $[M + Na]^+$ 249.0703, found 249.0708.

(6*aR**)-6,6-Difluoro-6*a*-phenyloctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-one (**8e**). According to the general procedure C, radical cyclization of **6f** (196 mg, 0.5 mmol) gave **8e** (129 mg, 91%) as a white solid after column chromatography (SiO_2 , hexanes) and then 5% EtOAc/hexanes). Mp 156–157 °C (CH_2Cl_2 /hexanes); IR ($CHCl_3$) 2959w, 2928m, 1778s, 1283w, 1179m, 1113m, 1004m cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$): δ 7.38–7.28 (m, 5H), 3.29–3.26 (m, 1H), 3.07 (dd, $J = 10.4, 4.6$, 1H), 2.90–2.88 (m, 1H), 2.70 (br.s, 1H), 2.67–2.50 (m, 1H), 1.84–1.71 (m, 4H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 175.4, 135.5, 128.7, 128.1, 128.1, 126.8 (dd, $J = 271.3, 246.7$ Hz), 126.4, 126.3, 91.4 (dd, $J = 31.8, 19.2$ Hz), 52.7 (d, $J = 3.3$ Hz), 50.6, 45.3 (dd, $J = 26.3, 20.8$ Hz), 43.3 (d, $J = 5.4$ Hz), 41.5, 40.0, 28.2 (d, $J = 9.0$ Hz); ^{19}F NMR (470 MHz, $CDCl_3$): δ -117.4 (d, $J = 239.7$ Hz, 1F), -93.6 (dd, $J = 239.7, 11.3$ Hz, 1F); MS: m/z (% relative intensity) 276 (M^+ , 55), 232 (66), 212 (27), 178 (100), 159 (6); HRMS (ESI-TOF) calcd for $C_{16}H_{14}F_2O_2Na$ $[M + Na]^+$ 299.0860, found 299.0836.

(6*aR**)-6,6-Difluoro-6*a*-(4-methoxyphenyl)octahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-one (**8f**). According to the general procedure C, radical cyclization of **6g** (83 mg, 0.2 mmol) gave **8f** (47 mg, 76%) as a white solid and recovered starting material (14 mg, 17%) after column chromatography (SiO_2 , hexanes) and then 5% EtOAc/hexanes). Mp 179–180 °C (CH_2Cl_2 /hexanes); IR ($CHCl_3$) 2966m, 1778s, 1614m, 1516s, 1465w, 1307m, 1258m, 1235m, 1180s, 1113m, 1069m, 1002m cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$): δ 7.29 (d, $J = 8.7$ Hz, 2H), 6.85 (d, $J = 8.7$ Hz, 2H), 3.74 (s, 3H), 3.26–3.24 (m, 1H), 3.08 (dd, $J = 10.4, 4.5$ Hz, 1H), 2.87 (br.s, 1H), 2.71 (br.s, 1H), 2.64–2.55 (m, 1H), 1.82–1.68 (m, 4H); ^{13}C NMR (125 MHz, $CDCl_3$): δ 175.5, 159.9, 127.6, 127.6, 127.5, 126.8 (dd, $J = 271.1, 246.0$ Hz), 113.6, 113.6, 91.4 (dd, $J = 31.8, 19.2$ Hz), 55.3, 52.4 (d, $J = 3.5$ Hz), 50.8, 45.3 (dd, $J = 26.3, 20.8$ Hz), 43.2 (d, $J = 5.3$ Hz), 41.4, 40.0, 28.2 (d, $J = 9.1$ Hz); ^{19}F NMR (470 MHz, $CDCl_3$): δ -117.8 (d, $J = 239.2$ Hz, 1F), -93.8 (dd, $J = 239.2, 11.3$ Hz, 1F); MS: m/z (% relative intensity) 306 (M^+ , 31), 262 (21), 208 (65), 207 (100); HRMS (ESI-TOF) calcd for $C_{17}H_{16}F_2O_3Na$ $[M + Na]^+$ 329.0965, found 329.0972.

(6*aS**)-6,6-Difluorooctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-2-one (**8g**). According to the general procedure C, radical

cyclization of **6h** (155 mg, 0.5 mmol) gave **8g** (94 mg, 94%) as a white solid after column chromatography (SiO₂, hexanes and then 5% EtOAc/hexanes). Mp 206–208 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2987m, 2970m, 1784s, 1371s, 1317m, 1236m, 1175s, 1059s cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 4.70–4.65 (m, 1H), 3.31–3.27 (m, 1H), 3.03 (ddd, *J* = 10.5, 4.4, 2.0 Hz, 1H), 2.77–2.74 (m, 2H), 2.59–2.53 (m, 1H), 1.87–1.80 (m, 3H), 1.72–1.67 (m, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 176.3, 127.4 (dd, *J* = 266.6, 241.1 Hz), 81.7 (dd, *J* = 41.7, 19.1 Hz), 48.9, 45.8 (d, *J* = 3.0 Hz), 44.1 (dd, *J* = 24.7, 21.2 Hz), 42.8 (d, *J* = 5.5 Hz), 41.7, 39.8, 28.0 (d, *J* = 9.3 Hz); ¹⁹F NMR (470 MHz, CDCl₃): δ -116.5 (d, *J* = 246.5 Hz, 1F), -98.9 (dt, *J* = 246.5, 11.5 Hz, 1F); MS: *m/z* (% relative intensity) 201 (M⁺ + H, 100), 200 (M⁺, 5), 156 (7), 135 (38), 133 (8), 83 (7); HRMS (ESI-TOF) calcd for C₁₀H₁₀F₂O₂Na [M + Na]⁺ 223.0547, found 223.0563.

(7a5*)-7,7-Difluoro-7a-methyloctahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9a**). According to the general procedure C, radical cyclization of **7a** (336 mg, 1.0 mmol) gave **9a** (203 mg, 89%) as a white solid after column chromatography (SiO₂, hexanes and then 5% EtOAc/hexanes) and preparative thin-layer chromatography, (SiO₂, 30% EtOAc/hexanes × 2). Mp 97–99 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2951m, 2874w, 1768s, 1458w, 1237m, 1195m, 1096s, 1085m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 2.70–2.63 (m, 1H), 2.50–2.43 (m, 1H), 2.33–2.22 (m, 1H), 2.08–2.00 (br, 2H), 1.80–1.65 (m, 2H), 1.64–1.48 (m, 4H), 1.47 (d, *J* = 4.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 178.3, 126.7 (dd, *J* = 269.0, 250.1 Hz), 89.6 (dd, *J* = 30.3, 18.6 Hz), 47.7, 45.2, 42.5 (dd, *J* = 24.9, 20.2 Hz), 27.7 (d, *J* = 5.9 Hz), 26.4, 24.8, 23.1 (dd, *J* = 7.7, 3.1 Hz), 19.0 (d, *J* = 7.9 Hz), 16.9; ¹⁹F NMR (376 MHz, CDCl₃): δ -123.9 (d, *J* = 236.9 Hz, 1F), -102.1 (dd, *J* = 236.9, 6.0 Hz, 1F); MS: *m/z* (% relative intensity) 229 (M⁺ + H, 100), 228 (13), 184 (47), 147 (4), 102 (4), 97 (11); HRMS (ESI-TOF) calcd for C₁₂H₁₄F₂O₂Na [M + Na]⁺ 251.0860, found 251.0857.

(7a5*)-7a-Ethyl-7,7-difluorooctahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9b**). According to the general procedure C, radical cyclization of **7b** (168 mg, 0.48 mmol) gave **9b** (104 mg, 89%) as a white solid after column chromatography (SiO₂, hexanes and 5% EtOAc/hexanes). Mp 51–52 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2947s, 2873m, 1778s, 1463m, 1222m, 1193m, 1094m, 1039m, 984m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 2.65 (dt, *J* = 10.0, 2.2 Hz, 1H), 2.50 (dd, *J* = 10.0, 3.7 Hz, 1H), 2.32–2.21 (m, 1H), 2.08–2.03 (br, 1H), 2.02–1.90 (m, 2H), 1.80–1.44 (m, 7H), 0.99 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 178.4, 127.2 (dd, *J* = 269.8, 250.2 Hz), 92.1 (dd, *J* = 29.3, 18.0 Hz), 45.6, 45.1, 42.9 (dd, *J* = 25.1, 20.4 Hz), 27.8 (d, *J* = 6.0 Hz), 26.5, 25.8 (d, *J* = 6.5 Hz), 24.8, 23.2 (dd, *J* = 7.7, 2.9 Hz), 17.0, 7.9 (d, *J* = 1.8 Hz); ¹⁹F NMR (376 MHz, CDCl₃): δ -120.8 (d, *J* = 238.0 Hz, 1F), -104.4 (dd, *J* = 238.0, 10.9 Hz, 1F); MS: *m/z* (% relative intensity) 243 (M⁺ + H, 100), 242 (M⁺, 79), 214 (17), 135 (27), 111 (10), 109 (59); HRMS (ESI-TOF) calcd for C₁₃H₁₆F₂O₂Na [M + Na]⁺ 265.1016, found 265.1013.

(7a5*)-7a-Butyl-7,7-difluorooctahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9c**). According to the general procedure C, radical cyclization of **7c** (238 mg, 0.63 mmol) gave **9c** (148 mg, 87%) as a white solid after column chromatography (SiO₂, hexanes and then 5% EtOAc/hexanes). Mp 54–55 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2958s, 2874m, 1771s, 1471w, 1243m, 1192m, 1095m, 992m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 2.64 (d, *J* = 9.9 Hz, 1H), 2.50 (dd, *J* = 9.9, 4.3 Hz, 1H), 2.32–2.21 (m, 1H), 2.08–1.97 (m, 2H), 1.96–1.85 (m, 1H), 1.80–1.68 (m, 2H), 1.64–1.23 (m, 9H), 0.85 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 178.4, 127.1 (dd, *J* = 269.9, 250.2 Hz), 91.8 (dd, *J* = 29.3, 17.9 Hz), 46.0, 45.0, 42.8 (dd, *J* = 25.1, 20.3 Hz), 32.6 (d, *J* = 5.7 Hz), 27.8 (d, *J* = 6.0 Hz), 26.5, 25.6 (d, *J* = 1.1 Hz), 24.8, 23.2 (dd, *J* = 7.7, 2.8 Hz), 22.9, 17.1, 13.9; ¹⁹F NMR (376 MHz, CDCl₃): δ -120.9 (d, *J* = 237.1 Hz, 1F), -103.9 (dd, *J* = 237.1, 12.0 Hz, 1F); MS: *m/z* (% relative intensity) 270 (M⁺, 21), 241 (100), 227 (24), 213 (19), 190 (11), 135 (16); HRMS (ESI-TOF) calcd for C₁₅H₁₈F₂O₂Na [M + Na]⁺ 293.1329, found 293.1326.

(7a5*)-7,7-Difluoro-7a-isopropyloctahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9d**). According to the general procedure C, radical cyclization of **7d** (78 mg, 0.2 mmol) gave **9d** (52 mg, 99%) as a white solid after column chromatography (SiO₂, hexanes and then

5% EtOAc/hexanes). Mp 75–76 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2949m, 1773s, 1471w, 1266w, 1184m, 1095m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 2.66–2.58 (br, 2H), 2.31–2.21 (m, 1H), 2.09–1.93 (m, 3H), 1.79–1.69 (m, 2H), 1.63–1.45 (m, 4H), 1.08 (d, *J* = 6.8 Hz, 3H), 0.93 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 176.6, 127.8 (dd, *J* = 271.4, 249.5 Hz), 94.2 (dd, *J* = 28.3, 17.0 Hz), 45.0, 44.3, 43.0 (dd, *J* = 25.2, 20.5 Hz), 30.7, 27.8 (d, *J* = 6.1 Hz), 26.6, 24.8, 23.2 (dd, *J* = 7.8, 2.7 Hz), 17.4 (d, *J* = 3.0 Hz), 17.1, 17.0; ¹⁹F NMR (376 MHz, CDCl₃): δ -118.0 (d, *J* = 239.3 Hz, 1F), -104.7 (dd, *J* = 239.3, 12.0 Hz, 1F); MS: *m/z* (% relative intensity) 256 (M⁺, 100), 213 (18), 149 (37); HRMS (ESI-TOF) calcd for C₁₄H₁₈F₂O₂Na [M + Na]⁺ 279.1173, found 279.1185.

(7a5*)-7,7-Difluoro-7a-vinyloctahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9e**). According to the general procedure C, radical cyclization of **7e** (349 mg, 1.0 mmol) gave **9e** (227 mg, 94%) as a white solid after column chromatography (SiO₂, hexanes and then 5% EtOAc/hexanes). Mp 105–107 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3028w, 2951m, 2874w, 1778s, 1295w, 1196m, 1180m, 1104m, 999m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 5.95 (ddd, *J* = 17.2, 11.0, 3.6 Hz, 1H), 5.49 (d, *J* = 17.2 Hz, 1H), 5.28 (d, *J* = 11.0 Hz, 1H), 2.75–2.58 (m, 2H), 2.39–2.26 (m, 1H), 2.19–2.02 (m, 2H), 1.85–1.68 (m, 2H), 1.67–1.44 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 177.8, 131.4 (d, *J* = 7.0 Hz), 127.0 (dd, *J* = 274.1, 248.1 Hz), 116.5, 90.5 (dd, *J* = 29.3, 18.8 Hz), 47.1, 44.6, 42.5 (dd, *J* = 24.8, 20.2 Hz), 28.2 (d, *J* = 5.6 Hz), 26.6, 24.8, 23.2 (dd, *J* = 7.5, 2.7 Hz), 17.0; ¹⁹F NMR (376 MHz, CDCl₃): δ -121.7 (d, *J* = 238.2 Hz, 1F), -99.7 (dd, *J* = 238.2, 10.4 Hz, 1F); MS: *m/z* (% relative intensity) 241 (M⁺ + H, 100), 240 (M⁺, 53), 196 (9), 169 (13), 159 (11), 115 (64), 109 (45), 105 (16), 77 (46); HRMS (ESI-TOF) calcd for C₁₃H₁₄F₂O₂Na [M + Na]⁺ 263.0860, found 263.0876.

(7aR*)-7,7-Difluoro-7a-phenyloctahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9f**). According to the general procedure C, radical cyclization of **7f** (399 mg, 1.0 mmol) gave **9f** (281 mg, 97%) as a white solid after column chromatography (SiO₂, hexanes and then 5% EtOAc/hexanes). Mp 123–124 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2951m, 2874w, 1777s, 1279w, 1180m, 1060m, 1012m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.39–7.27 (m, 5H), 3.08–3.00 (m, 1H), 2.74 (dt, *J* = 10.1, 2.2 Hz, 1H), 2.47–2.38 (m, 1H), 2.37–2.30 (m, 1H), 2.16–2.10 (br, 1H), 1.90–1.79 (m, 2H), 1.78–1.50 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 177.5, 135.8, 128.7, 128.3, 128.3, 126.4 (dd, *J* = 272.4, 250.4 Hz), 126.0, 126.0, 92.0 (dd, *J* = 31.2, 18.5 Hz), 47.8 (d, *J* = 2.2 Hz), 45.0, 42.6 (dd, *J* = 25.2, 20.2 Hz), 29.5 (d, *J* = 5.6 Hz), 26.7, 24.8, 23.3 (dd, *J* = 7.4, 2.6 Hz), 17.3; ¹⁹F NMR (376 MHz, CDCl₃): δ -122.7 (d, *J* = 235.5 Hz, 1F), -94.4 (dd, *J* = 235.5, 11.1 Hz, 1F); MS: *m/z* (% relative intensity) 291 (M⁺ + H, 27), 246 (82), 159 (15), 105 (51), 77 (100); HRMS (ESI-TOF) calcd for C₁₇H₁₆F₂O₂Na [M + Na]⁺ 313.1016, found 313.1018.

(7aR*)-7,7-Difluoro-7a-(4-methoxyphenyl)octahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9g**). According to the general procedure C, radical cyclization of **7g** (269 mg, 0.63 mmol) gave **9g** (179 mg, 89%) as a white solid after column chromatography (SiO₂, hexanes and then 5% EtOAc/hexanes). Mp 186–187 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2951w, 2874w, 1777s, 1614w, 1516m, 1256m, 1180s, 1065m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.29 (d, *J* = 8.4 Hz, 2H), 6.84 (d, *J* = 8.4 Hz, 2H), 3.74 (s, 3H), 3.06–2.96 (br, 1H), 2.73 (d, *J* = 10.0 Hz, 1H), 2.40 (dd, *J* = 10.7, 10.7 Hz, 1H), 2.34–2.25 (br, 1H), 2.15–2.08 (br, 1H), 1.90–1.77 (m, 2H), 1.76–1.50 (m, 4H); ¹³C NMR (100 MHz, CDCl₃): δ 177.7, 159.8, 127.7, 127.3, 127.3, 126.4 (dd, *J* = 272.3, 249.8 Hz), 113.7, 113.7, 91.9 (dd, *J* = 31.3, 18.7 Hz), 55.3, 47.6 (d, *J* = 1.3 Hz), 45.0, 42.5 (dd, *J* = 25.5, 20.2 Hz), 29.3 (d, *J* = 5.7 Hz), 26.6, 24.8, 23.3 (dd, *J* = 7.2, 2.2 Hz), 17.2; ¹⁹F NMR (376 MHz, CDCl₃): δ -123.0 (d, *J* = 235.6 Hz, 1F), -94.0 (d, *J* = 235.6 Hz, 1F); MS: *m/z* (% relative intensity) 320 (M⁺, 68), 276 (100), 189 (6), 135 (24), 77 (18); HRMS (ESI-TOF) calcd for C₁₈H₁₈F₂O₃Na [M + Na]⁺ 343.1122, found 343.1134.

(7a5*)-7,7-Difluoro-7a-isopropyloctahydro-3,6-methanoindeno[1,7-bc]furan-2(2a1H)-one (**9h**). According to the general procedure C, radical cyclization of **7h** (303 mg, 0.94 mmol) gave **9h** (174 mg, 87%) as a white solid after column chromatography (SiO₂, hexanes and then 5% EtOAc/hexanes). Mp 185–187 °C (CH₂Cl₂/hexanes); IR (CHCl₃)

2951m, 2874w, 1774s, 1368m, 1240m, 1169s, 1094s, 1058s cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 4.73 (dd, $J = 14.0, 7.3$ Hz, 1H), 3.05–2.96 (m, 1H), 2.63 (d, $J = 10.1$ Hz, 1H), 2.34–2.24 (m, 1H), 2.16–2.07 (br, 2H), 1.89–1.78 (m, 1H), 1.77–1.54 (m, 5H); ^{13}C NMR (100 MHz, CDCl_3): δ 178.9, 126.8 (dd, $J = 267.2, 245.0$ Hz), 82.4 (dd, $J = 40.5, 18.6$ Hz), 42.9, 41.5 (dd, $J = 23.7, 20.4$ Hz), 40.7, 28.3 (d, $J = 5.6$ Hz), 26.5, 25.1, 23.0 (dd, $J = 7.6, 3.1$ Hz), 17.0; ^{19}F NMR (376 MHz, CDCl_3): δ –122.6 (d, $J = 242.1$ Hz, 1F), –98.6 (dt, $J = 242.1, 12.8$ Hz, 1F); MS: m/z (% relative intensity) 215 ($\text{M}^+ + \text{H}$, 61), 214 (M^+ , 40), 135 (21), 133 (13), 109 (60), 91 (100), 83 (18), 77 (71); HRMS (ESI-TOF) calcd for $\text{C}_{11}\text{H}_{12}\text{F}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 237.0703, found 237.0700.

Synthesis of gem-Difluoromethylated Polycyclic Cage Compounds 10 and 11 from Compounds 8 and 9. *General Procedure D.* A solution of 8 or 9 (0.5 mmol) in dry THF (4 mL) was treated with a THF solution of alkyl- or arylmagnesium chloride (or bromide) (2.5 mmol) at 0 °C under an argon atmosphere. After stirring at 0 °C to room temperature for 1 h, 10% HCl (2 mL) was added to the reaction mixture. The aqueous phase was extracted with EtOAc (4 \times 5 mL). The combined organic phase was washed with brine (10 mL) and dried over anhydrous Na_2SO_4 . After removal of the solvents, the crude product was purified by column chromatography (SiO_2) or preparative thin-layer chromatography (SiO_2) to give the required products.

($2\text{S}^*, 6\text{aR}^*$)-6,6-Difluoro-2-methyl-6a-phenyloctahydro-2H-3,5-methanopentaleno[1,6-bc]furan-2-ol (**10a**). According to the general procedure D, the reaction of 8e (56 mg, 0.2 mmol) with methylmagnesium chloride (3.0 M in THF, 0.33 mL, 1.0 mmol) gave **10a** (51 mg, 88%) as a white solid after column chromatography (SiO_2 , 20% EtOAc/hexanes) and then preparative thin-layer chromatography (SiO_2 , 80% CH_2Cl_2 /hexanes \times 3). Mp 156–157 °C (CH_2Cl_2 /hexanes); IR (KBr) 3393br, 2972m, 1450w, 1380m, 1342m, 1172s, 1093s cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.43–7.36 (m, 2H), 7.31–7.17 (m, 3H), 3.29 (dd, $J = 7.9, 6.4$ Hz, 1H), 2.81–2.73 (br, 1H), 2.64–2.58 (m, 1H), 2.51–2.40 (m, 1H), 2.32–2.26 (m, 1H), 2.13–2.05 (m, 1H), 1.83 (s, 1H), 1.64–1.55 (m, 3H), 1.53 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 139.6, 127.7, 127.7, 127.6, 127.3 (dd, $J = 268.8, 244.6$ Hz), 126.8, 126.7, 106.3, 91.6 (dd, $J = 29.2, 17.8$ Hz), 59.1, 55.2 (d, $J = 3.7$ Hz), 45.7 (dd, $J = 25.0, 21.5$ Hz), 43.0 (d, $J = 6.1$ Hz), 41.3, 37.8, 27.4 (d, $J = 9.2$ Hz), 23.2; ^{19}F NMR (376 MHz, CDCl_3): δ –121.2 (d, $J = 233.3$ Hz, 1F), –99.1 (dd, $J = 233.3, 8.6$ Hz, 1F); MS: m/z (% relative intensity) 292 (M^+ , 2), 277 (19), 275 (36), 273 (11), 254 (14), 178 (100), 177 (57); HRMS (ESI-TOF) calcd for $\text{C}_{17}\text{H}_{18}\text{F}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 315.1173, found 315.1176.

($2\text{S}^*, 6\text{aR}^*$)-6,6-Difluoro-6a-(4-methoxyphenyl)-2-methyloctahydro-2H-3,5-methanopentaleno[1,6-bc]furan-2-ol (**10b**). According to the general procedure D, the reaction of 8f (40 mg, 0.13 mmol) with methylmagnesium chloride (3.0 M in THF, 0.22 mL, 0.65 mmol) gave **10b** (39 mg, 94%) as a white solid after column chromatography (SiO_2 , 20% EtOAc/hexanes) and then preparative thin-layer chromatography (SiO_2 , 80% CH_2Cl_2 /hexanes \times 3). Mp 153–154 °C (CH_2Cl_2 /hexanes); IR (CHCl_3) 3589w, 3409br, 2962m, 1612m, 1515s, 1342w, 1250m, 1177m, 1099m, 1035m cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.26 (d, $J = 8.6$ Hz, 2H), 6.76 (d, $J = 8.6$ Hz, 2H), 3.67 (s, 3H), 3.22–3.14 (m, 1H), 2.70–2.64 (br, 1H), 2.57–2.50 (m, 1H), 2.44–2.33 (m, 1H), 2.25–2.18 (m, 1H), 2.05–1.97 (m, 1H), 1.87 (s, 1H), 1.58–1.48 (m, 3H), 1.45 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 159.1, 131.8, 127.9, 127.9, 127.3 (dd, $J = 268.8, 243.9$ Hz), 113.2, 112.9, 106.2, 91.3 (dd, $J = 29.2, 17.7$ Hz), 59.3, 55.2, 54.9 (d, $J = 3.7$ Hz), 45.6 (dd, $J = 25.0, 21.3$ Hz), 42.9 (d, $J = 6.0$ Hz), 41.2, 37.8, 27.4 (d, $J = 9.2$ Hz), 23.2; ^{19}F NMR (376 MHz, CDCl_3): δ –121.5 (d, $J = 233.1$ Hz, 1F), –98.9 (dd, $J = 233.1, 10.5$ Hz, 1F); MS: m/z (% relative intensity) 322 (M^+ , 5), 305 (18), 303 (100), 284 (8), 262 (10), 185 (14); HRMS (ESI-TOF) calcd for $\text{C}_{18}\text{H}_{20}\text{F}_2\text{O}_3\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 345.1278, found 345.1279.

($2\text{R}^*, 7\text{aS}^*$)-7,7-Difluoro-7a-methyl-2-phenyldecahydro-3,6-methanoindenol[1,7-bc]furan-2-ol (**11a**). According to the general procedure D, the reaction of 9a (46 mg, 0.2 mmol) with phenylmagnesium chloride (2.0 M in THF, 0.50 mL, 1.0 mmol)

gave **11a** (56 mg, 91%) as a white solid after preparative thin-layer chromatography (SiO_2 , 80% CH_2Cl_2 /hexanes). Mp 163–164 °C (CH_2Cl_2 /hexanes); IR (CHCl_3) 3580m, 3384br, 2945s, 2871m, 1449m, 1334m, 1160m, 1094m, 996m cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.47–7.40 (m, 2H), 7.28–7.17 (m, 3H), 2.84 (d, $J = 3.6$ Hz, 1H), 2.71–2.65 (m, 1H), 2.44 (d, $J = 8.7$ Hz, 1H), 2.12–2.03 (m, 1H), 2.01–1.95 (m, 1H), 1.77–1.69 (m, 1H), 1.67–1.48 (m, 2H), 1.47 (d, $J = 4.4$ Hz, 3H), 1.38–1.16 (m, 2H), 1.13–1.03 (m, 1H), 0.93–0.87 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 141.3, 128.2, 128.1, 128.1, 127.5 (dd, $J = 266.7, 247.1$ Hz), 126.2, 126.2, 109.5, 90.2 (dd, $J = 28.7, 17.4$ Hz), 54.4, 51.6 (d, $J = 2.0$ Hz), 42.2 (dd, $J = 23.7, 20.5$ Hz), 29.0 (d, $J = 6.0$ Hz), 26.9, 24.2, 22.9 (d, $J = 7.0$ Hz), 20.9 (d, $J = 7.0$ Hz), 17.8; ^{19}F NMR (376 MHz, CDCl_3): δ –127.3 (d, $J = 228.6$ Hz, 1F), –107.0 (d, $J = 228.6$ Hz, 1F); MS: m/z (% relative intensity) 306 (M^+ , 0.3), 287 (100), 286 (76), 268 (2), 229 (5), 225 (5), 191 (11), 175 (7); HRMS (ESI-TOF) calcd for $\text{C}_{18}\text{H}_{20}\text{F}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 329.1329, found 329.1327.

($2\text{R}^*, 7\text{aS}^*$)-2-(2,4-Dimethoxyphenyl)-7,7-difluoro-7a-methyldecahydro-3,6-methanoindenol[1,7-bc]furan-2-ol (**11b**). According to the general procedure D, the reaction of 9a (46 mg, 0.24 mmol) with 2,4-dimethoxyphenylmagnesium bromide (0.5 M in THF, 2.40 mL, 1.2 mmol) gave **11b** (71 mg, 80%) as a white solid after preparative thin-layer chromatography (SiO_2 , 40% CH_2Cl_2 /hexanes). Mp 143–144 °C (CH_2Cl_2 /hexanes); IR (CHCl_3) 3581br, 2941s, 2870w, 1614s, 1588m, 1506s, 1466m, 1456m, 1317m, 1285m, 1160m, 1094m cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.57–7.55 (m, 1H), 6.39–6.36 (m, 2H), 3.75 (s, 3H), 3.72 (s, 3H), 3.14 (s, 1H), 2.78–2.72 (m, 1H), 2.70–2.62 (m, 1H), 2.09–2.00 (m, 1H), 1.99–1.93 (m, 1H), 1.71–1.51 (m, 3H), 1.48 (d, $J = 4.4$ Hz, 3H), 1.42–1.32 (m, 1H), 1.31–1.21 (m, 1H), 1.11–1.01 (m, 1H), 0.99–0.92 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 160.8, 156.9, 127.9, 127.6 (dd, $J = 266.9, 247.0$ Hz), 122.1, 108.2, 103.8, 98.9, 89.3 (dd, $J = 28.7, 17.4$ Hz), 55.6, 55.3, 53.7, 51.3 (d, $J = 2.1$ Hz), 42.1 (dd, $J = 23.5, 20.5$ Hz), 29.0 (d, $J = 6.3$ Hz), 26.9, 24.7, 22.9 (d, $J = 7.0$ Hz), 20.7 (d, $J = 6.6$ Hz), 17.9; ^{19}F NMR (376 MHz, CDCl_3): δ –127.4 (d, $J = 228.2$ Hz, 1F), –107.2 (d, $J = 228.2$ Hz, 1F); MS: m/z (% relative intensity) 366 (M^+ , 0.1), 348 (100), 347 (41), 330 (2), 328 (2), 212 (7), 165 (19); HRMS (ESI-TOF) calcd for $\text{C}_{20}\text{H}_{24}\text{F}_2\text{O}_4\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 389.1540, found 389.1537.

($2\text{R}^*, 7\text{aS}^*$)-7a-Butyl-7,7-difluoro-2-phenyldecahydro-3,6-methanoindenol[1,7-bc]furan-2-ol (**11c**). According to the general procedure D, the reaction of 9c (124 mg, 0.46 mmol) with phenylmagnesium chloride (2.0 M in THF, 1.15 mL, 2.29 mmol) gave **11c** (110 mg, 69%) as a colorless viscous oil after preparative thin-layer chromatography (SiO_2 , 20% EtOAc/hexanes). IR (CHCl_3) 3580m, 3384br, 2953s, 2872m, 1449w, 1337m, 1093m, 1058m, 988m cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 7.52–7.44 (m, 2H), 7.30–7.14 (m, 3H), 2.68 (s, 1H), 2.67–2.60 (m, 1H), 2.47–2.39 (m, 1H), 2.10–2.00 (m, 1H), 1.99–1.92 (m, 1H), 1.91–1.81 (m, 1H), 1.80–1.67 (m, 2H), 1.66–1.43 (m, 4H), 1.39–1.16 (m, 4H), 1.10–1.01 (m, 1H), 0.96–0.90 (br, 1H), 0.85 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 141.6, 128.3 (dd, $J = 267.8, 248.2$ Hz), 128.2, 128.1, 128.1, 126.4, 126.4, 109.5, 92.4 (dd, $J = 27.8, 16.6$ Hz), 54.0, 51.3 (d, $J = 1.6$ Hz), 42.8 (dd, $J = 24.0, 20.6$ Hz), 36.1 (d, $J = 4.2$ Hz), 29.0 (d, $J = 6.3$ Hz), 26.9, 26.5, 24.3, 23.4, 22.8 (dd, $J = 8.0, 1.4$ Hz), 17.8, 14.1; ^{19}F NMR (376 MHz, CDCl_3): δ –121.8 (d, $J = 228.4$ Hz, 1F), –107.4 (d, $J = 228.4$ Hz, 1F); MS: m/z (% relative intensity) 348 (M^+ , 0.5), 331 (100), 330 (73), 329 (7), 312 (3), 310 (3), 291 (6), 271 (0.7), 267 (4), 217 (3), 105 (30); HRMS (ESI-TOF) calcd for $\text{C}_{21}\text{H}_{26}\text{F}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 371.1799, found 371.1796.

(7aR^*)-7,7-Difluoro-2-methyl-7a-phenyldecahydro-3,6-methanoindenol[1,7-bc]furan-2-ol (**11d**). According to the general procedure D, the reaction of 9f (58 mg, 0.2 mmol) with methylmagnesium chloride (2.0 M in THF, 0.50 mL, 1.0 mmol) gave a 97:3 diastereomeric mixture of **11d** (47 mg, 77%) as a white solid after preparative thin-layer chromatography (SiO_2 , 80% CH_2Cl_2 /hexanes \times 2). Mp 124–125 °C (CH_2Cl_2 /hexanes); IR (CHCl_3) 3589m, 3431br, 2945s, 2872m, 1497m, 1448m, 1385m, 1333m, 1112m, 1055m, 1009s, 917m cm^{-1} ; ^1H NMR (400 MHz, CDCl_3 , the minor isomer marked*): δ 7.40–7.34 (m, 2H), 7.35–7.18 (m, 3H), 3.18–3.10 (m, 1H), 2.30–2.20 (m, 3H), 2.04–1.96 (m, 1H), 1.88 (s,

1H), 1.82–1.61 (m, 3H), 1.55–1.40 (m, 3H), 1.47 (s, 3H), 1.18 (s, 3H*). Due to low intensity of ¹H NMR signals of **11d**, some peaks of **11d** could not be detected by ¹H NMR. ¹³C NMR (100 MHz, CDCl₃, the minor isomer marked*): δ 140.1, 127.8, 127.8, 127.6, 126.7 (dd, J = 269.5, 247.4 Hz), 126.3, 126.3, 108.2*, 108.0, 92.2 (dd, J = 28.7, 17.4 Hz), 52.7, 52.6* (d, J = 2.6 Hz), 52.1 (d, J = 2.7 Hz), 51.0*, 42.4 (dd, J = 23.8, 20.4 Hz), 30.7* (d, J = 6.2 Hz), 30.3 (d, J = 6.1 Hz), 28.5*, 26.7, 26.4*, 24.5* (d, J = 7.4 Hz), 24.1, 23.6, 23.5 (d, J = 7.4 Hz), 22.5*, 18.0*, 17.9. Due to low intensity of ¹³C NMR signals of **11d**, some peaks of **11d** could not be detected by ¹³C NMR. ¹⁹F NMR (376 MHz, CDCl₃, the minor isomer marked*): δ -125.9 (d, J = 228.5 Hz, 1F), -125.2 (d, J = 227.3 Hz, 1F*), -101.9 (dd, J = 228.5, 7.7 Hz, 1F), -100.4 (dd, J = 227.3, 9.9 Hz, 1F*); MS: *m/z* (% relative intensity) 306 (M⁺, 1), 289 (28), 287 (34), 268 (9), 246 (100), 159 (19); HRMS (ESI-TOF) calcd for C₁₈H₂₀F₂O₂Na [M + Na]⁺ 329.1329, found 329.1327.

(2*R**,7*aR**)-7,7-Difluoro-2-(4-methoxyphenyl)-7*a*-phenyldecahydro-3,6-methanoindeno[1,7-*bc*]furan-2-ol (**11e**). According to the general procedure D, the reaction of **9f** (126 mg, 0.43 mmol) with 4-methoxyphenylmagnesium bromide (0.5 M in THF, 4.30 mL, 2.2 mmol) gave **11e** (129 mg, 75%) as a white solid after preparative thin-layer chromatography (SiO₂, 20% EtOAc/hexanes). Mp 99–101 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3579br, 2942s, 2871m, 1614s, 1514s, 1302m, 1244s, 1172s, 1041m, 1052m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.64–7.53 (m, 4H), 7.43–7.30 (m, 3H), 6.97–6.90 (m, 2H), 3.85 (s, 3H), 3.42–3.34 (m, 1H), 2.67–2.60 (m, 1H), 2.57–2.49 (br, 1H), 2.45–2.30 (m, 2H), 2.10–2.00 (m, 1H), 1.91–1.73 (m, 2H), 1.58–1.39 (m, 2H), 1.37–1.27 (m, 1H), 1.22–1.14 (br, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 159.5, 140.2, 133.4, 127.7, 127.7, 127.6, 127.6, 127.5, 127.0 (dd, J = 269.7, 247.8 Hz), 126.4, 126.4, 113.5, 113.5, 109.4, 92.4 (dd, J = 28.8, 17.3 Hz), 55.3, 54.4, 52.4 (d, J = 2.4 Hz), 42.4 (dd, J = 23.8, 20.3 Hz), 30.6 (d, J = 5.9 Hz), 26.9, 24.3, 23.2 (d, J = 7.2 Hz), 18.0; ¹⁹F NMR (376 MHz, CDCl₃): δ -125.5 (d, J = 229.4 Hz, 1F), -100.4 (d, J = 229.4 Hz, 1F); MS: *m/z* (% relative intensity) 381 (M⁺ - OH, 69), 380 (100), 360 (30), 159 (4), 136 (11), 135 (79), 105 (10), 77 (22); HRMS (ESI-TOF) calcd for C₂₄H₂₄F₂O₃Na [M + Na]⁺ 421.1591, found 421.1592.

(2*R**,7*aR**)-2-(2,4-Dimethoxyphenyl)-7,7-difluoro-7*a*-phenyldecahydro-3,6-methanoindeno[1,7-*bc*]furan-2-ol (**11f**). According to the general procedure D, the reaction of **9f** (59 mg, 0.2 mmol) with 2,4-dimethoxyphenylmagnesium bromide (0.5 M in THF, 2.0 mL, 1.0 mmol) gave **11f** (57 mg, 67%) as a white solid after column chromatography (SiO₂, hexanes–80% CH₂Cl₂/hexanes) and then preparative thin-layer chromatography (SiO₂, 10:20:70% EtOAc:CH₂Cl₂:hexanes). Mp 207–208 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3580br, 2941s, 2870m, 1614s, 1588s, 1506s, 1466m, 1317m, 1286m, 1261m, 1155m, 1051m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, J = 8.5 Hz, 1H), 7.48 (d, J = 7.8 Hz, 2H), 7.32–7.17 (m, 3H), 6.44 (dd, J = 8.5, 2.3 Hz, 1H), 6.39 (d, J = 2.3 Hz, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 3.28–3.21 (m, 1H), 2.85 (s, 1H), 2.83 (s, 1H), 2.33–2.27 (br, 1H), 2.26–2.17 (m, 1H), 1.83–1.75 (m, 1H), 1.74–1.62 (m, 2H), 1.50–1.40 (m, 1H), 1.39–1.29 (m, 1H), 1.21–1.12 (m, 1H), 1.11–1.06 (br, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 161.0, 157.1, 140.1, 128.0, 127.7, 127.7, 127.5, 127.1 (dd, J = 269.7, 247.7 Hz), 126.4, 126.4, 121.9, 108.1, 104.0, 99.1, 91.6 (dd, J = 28.7, 17.4 Hz), 55.6, 55.4, 53.5, 52.1 (d, J = 2.2 Hz), 42.3 (dd, J = 23.6, 20.5 Hz), 30.7 (d, J = 6.1 Hz), 26.9, 24.6, 23.2 (d, J = 7.2 Hz), 18.1; ¹⁹F NMR (376 MHz, CDCl₃): δ -125.6 (d, J = 226.4 Hz, 1F), -100.8 (dd, J = 226.4, 9.8 Hz, 1F); MS: *m/z* (% relative intensity) 428 (M⁺, 1), 411 (100), 410 (99), 409 (38), 390 (12), 351 (4), 253 (11), 246 (32), 182 (17), 165 (62), 77 (17); HRMS (ESI-TOF) calcd for C₂₅H₂₆F₂O₄Na [M + Na]⁺ 451.1697, found 451.1695.

(7*aR**)-2-Ethyl-7,7-difluoro-7*a*-(4-methoxyphenyl)decahydro-3,6-methanoindeno[1,7-*bc*]furan-2-ol (**11g**). According to the general procedure D, the reaction of **9g** (65 mg, 0.2 mmol) with ethylmagnesium chloride (2.0 M in THF, 0.50 mL, 1.0 mmol) gave a 92:8 diastereomeric mixture of **11g** (55 mg, 85%) as a white solid after preparative thin-layer chromatography (SiO₂, 80% CH₂Cl₂/hexanes × 2). Mp 77–79 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3588br, 3020w, 2943m, 2872w, 1613w, 1514s, 1466w, 1249m, 1178m, 1062m, 947m

cm⁻¹; ¹H NMR (400 MHz, CDCl₃, the minor isomer marked*): δ 7.31–7.24 (m, 2H), 6.84–6.76 (m, 2H), 3.73 (s, 3H*), 3.72 (s, 3H), 3.16–3.08 (m, 1H), 2.92–2.86 (m, 1H*), 2.32–2.19 (m, 3H), 2.17–2.12 (m, 1H*), 2.06–1.98 (m, 1H), 1.85–1.61 (m, 6H), 1.60–1.40 (m, 3H), 1.35 (q, J = 7.2 Hz, 2H*), 0.95 (t, J = 7.5 Hz, 3H), 0.77 (t, J = 7.2 Hz, 3H*). Due to low intensity of ¹H NMR signals of **11g**, some peaks of **11g** could not be detected by ¹H NMR. ¹³C NMR (100 MHz, CDCl₃, the minor isomer marked*): δ 159.0, 132.5, 127.5*, 127.5*, 127.4, 127.4, 126.7 (dd, J = 269.5, 246.7 Hz), 113.2, 113.2, 113.1*, 113.1*, 110.1*, 109.7, 91.6 (dd, J = 28.7, 17.5 Hz), 55.2, 52.1* (d, J = 2.7 Hz), 51.8 (d, J = 2.7 Hz), 51.4, 49.4*, 42.3* (dd, J = 24.1, 20.3 Hz), 42.2 (dd, J = 24.0, 20.4 Hz), 33.3*, 30.5* (d, J = 6.3 Hz), 30.1 (d, J = 6.1 Hz), 29.2, 26.8, 26.5*, 24.6* (d, J = 7.6 Hz), 23.8 (d, J = 7.3 Hz), 23.7, 22.6*, 17.9, 8.2, 7.5*. Due to low intensity of ¹³C NMR signals of **11g**, some peaks of **11g** could not be detected by ¹³C NMR. ¹⁹F NMR (376 MHz, CDCl₃, the minor isomer marked*): δ -126.3 (d, J = 228.0 Hz, 1F), -125.4 (d, J = 226.6 Hz, 1F*), -101.0 (dd, J = 228.0, 7.5 Hz, 1F), -99.2 (dd, J = 226.6, 9.6 Hz, 1F*); MS: *m/z* (% relative intensity) 350 (M⁺, 0.3), 333 (17), 332 (78), 331 (100), 301 (70); HRMS (ESI-TOF) calcd for C₂₀H₂₄F₂O₃Na [M + Na]⁺ 373.1591, found 373.1597.

(2*R**,7*aR**)-7,7-Difluoro-7*a*-(4-methoxyphenyl)-2-phenyldecahydro-3,6-methanoindeno[1,7-*bc*]furan-2-ol (**11h**). According to the general procedure D, the reaction of **9g** (65 mg, 0.2 mmol) with phenylmagnesium chloride (2.0 M in THF, 0.50 mL, 1.0 mmol) gave **11h** (54 mg, 68%) as a white solid after column chromatography (SiO₂, hexanes–80% CH₂Cl₂/hexanes) and then preparative thin-layer chromatography (SiO₂, 80% CH₂Cl₂/hexanes). Mp 207–209 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3420br, 2943m, 2872w, 1612w, 1514s, 1247m, 1178m, 1063m, 997m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.62–7.56 (m, 2H), 7.41–7.35 (m, 2H), 7.34–7.23 (m, 3H), 6.85–6.79 (m, 2H), 3.73 (s, 3H), 3.31–3.25 (m, 1H), 2.61–2.55 (m, 1H), 2.28 (s, 1H), 2.30–2.20 (m, 2H), 1.98–1.88 (m, 1H), 1.79–1.62 (m, 2H), 1.47–1.27 (m, 2H), 1.24–1.15 (m, 1H), 1.08–1.01 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 159.0, 141.1, 132.3, 128.3, 128.2, 128.2, 127.5, 127.4, 126.9 (dd, J = 269.6, 247.2 Hz), 126.3, 126.3, 113.2, 113.2, 109.3, 92.3 (dd, J = 29.5, 18.2 Hz), 55.2, 54.4, 52.2 (d, J = 2.6 Hz), 42.3 (dd, J = 24.0, 20.4 Hz), 30.5 (d, J = 6.0 Hz), 26.9, 24.2, 23.1 (d, J = 7.3 Hz), 18.0; ¹⁹F NMR (376 MHz, CDCl₃): δ -126.0 (d, J = 227.2 Hz, 1F), -100.4 (dd, J = 227.2, 9.2 Hz, 1F); MS: *m/z* (% relative intensity) 398 (M⁺, 3), 379 (17), 360 (46), 276 (57), 255 (100), 235 (38), 105 (57), 77 (29); HRMS (ESI-TOF) calcd for C₂₄H₂₄F₂O₃Na [M + Na]⁺ 421.1591, found 421.1600.

(7*aS**)-2-Butyl-7,7-difluorodecahydro-3,6-methanoindeno[1,7-*bc*]furan-2-ol (**11i**). According to the general procedure D, the reaction of **9h** (43 mg, 0.2 mmol) with butylmagnesium chloride (2.0 M in THF, 0.5 mL, 1.0 mmol) gave a 99:1 diastereomeric mixture of **11i** (38 mg, 69%) as a white solid after column chromatography (SiO₂, hexanes–80% CH₂Cl₂/hexanes). Mp 88–90 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3420br, 2950s, 2872m, 1469w, 1458w, 1369m, 1359m, 1155m, 1094m, 1062s cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 4.29 (dd, J = 13.3, 7.0 Hz, 1H), 3.03 (dd, J = 14.1, 7.1 Hz, 1H), 2.15–2.01 (m, 2H), 1.98 (s, 1H), 1.97–1.91 (m, 1H), 1.87–1.78 (m, 1H), 1.76–1.55 (m, 5H), 1.57–1.16 (m, 7H), 0.85 (t, J = 7.1 Hz, 3H). Due to low intensity of ¹H NMR signals of **11i**, all peaks of the minor isomer of **11i** could not be detected by ¹H NMR. ¹³C NMR (100 MHz, CDCl₃): δ 127.4 (dd, J = 265.9, 242.5 Hz), 110.2, 83.1 (dd, J = 37.1, 17.4 Hz), 49.7, 44.6, 41.1 (dd, J = 22.1, 20.9 Hz), 36.3, 29.0 (d, J = 6.0 Hz), 27.1, 26.1, 23.7, 23.4 (d, J = 6.3 Hz), 23.0, 17.8, 14.0. Due to low intensity of ¹³C NMR signals of **11i**, all peaks of the minor isomer of **11i** could not be detected by ¹³C NMR. ¹⁹F NMR (376 MHz, CDCl₃, the minor isomer marked*): δ -125.3 (d, J = 232.9 Hz, 1F), -123.6 (d, J = 233.7 Hz, 1F*), -104.1 (dt, J = 232.9, 10.5 Hz, 1F), -101.7 (dt, J = 233.7, 13.2 Hz, 1F*); MS: *m/z* (% relative intensity) 272 (M⁺, 2), 253 (100), 240 (11), 234 (7), 141 (12), 107 (31), 102 (28); HRMS (ESI-TOF) calcd for C₁₅H₂₂F₂O₂Na [M + Na]⁺ 295.1486, found 295.1489.

Synthesis of gem-Difluoromethylenated Polycyclic Cage Compounds 12a, 14a, and 16a from 8a. A solution of **8a** (107 mg, 0.5 mmol) in dry THF (4 mL) was treated with a THF solution of phenylmagnesium chloride (2.0 M in THF, 1.25 mL, 2.5 mmol) at 0

°C. The reaction mixture was then heated at reflux overnight (15 h), cooled to room temperature, and quenched with 10% HCl (2 mL). The aqueous phase was extracted with EtOAc (4 × 5 mL). The combined organic phase was washed with brine (10 mL) and dried over anhydrous Na₂SO₄. After removal of the solvents, the crude product was treated with a catalytic amount of *p*-TsOH in dry CH₂Cl₂ (12 mL) under reflux for overnight (15 h). The reaction was quenched with saturated NaHCO₃ and extracted with CH₂Cl₂ (3 × 10 mL). The combined organic phase was washed with brine (10 mL) and dried over anhydrous Na₂SO₄. After removal of the solvents, the crude product was purified by preparative thin-layer chromatography (SiO₂, 10:20:30% EtOAc:CH₂Cl₂:hexanes and then 80% CH₂Cl₂/hexanes × 3) to give **12a** (105 mg, 59%), **14a** (8 mg, 6%), and **16a** (46 mg, 26%), each as a white solid.

(6*aS**)-6,6-Difluoro-6*a*-methyl-2,2-diphenyloctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan (**12a**). Mp 171–172 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2963m, 2878w, 1449m, 1344m, 1163m, 1095s, 1075s, 1015m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.45–7.32 (m, 4H), 7.21–7.11 (m, 4H), 7.10–6.99 (m, 2H), 3.67–3.59 (m, 1H), 2.64–2.57 (m, 1H), 2.56–2.50 (m, 1H), 2.29–2.19 (m, 1H), 2.09–2.02 (m, 1H), 1.95–1.87 (m, 1H), 1.60–1.52 (m, 1H), 1.47–1.40 (m, 1H), 1.21–1.11 (m, 1H), 0.99 (d, *J* = 4.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 147.3, 144.9, 128.4 (dd, *J* = 266.2, 243.7 Hz), 128.1, 128.1, 127.9, 127.9, 126.8, 126.0, 125.9, 125.9, 125.6, 125.6, 89.1, 88.2 (dd, *J* = 29.1, 18.2 Hz), 56.5, 55.7 (d, *J* = 3.8 Hz), 45.2 (dd, *J* = 24.5, 21.5 Hz), 42.8 (d, *J* = 6.3 Hz), 40.9, 39.1, 27.3 (d, *J* = 9.4 Hz), 19.0 (d, *J* = 5.6 Hz); ¹⁹F NMR (376 MHz, CDCl₃): δ -123.1 (d, *J* = 231.6 Hz, 1F), -103.9 (d, *J* = 231.6 Hz, 1F); MS: *m/z* (% relative intensity) 352 (M⁺, 16), 275 (100), 206 (22), 77 (13); HRMS (ESI-TOF) calcd for C₂₃H₂₂F₂O₂Na [M + Na]⁺ 375.1536, found 375.1541.

((3*S**,4*R**)-2,2-Difluoro-3-hydroxy-3-methyloctahydro-1,5-methanopentalen-4-yl)(phenyl)methanone (**14a**). Mp 125–126 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3602m, 3415br, 2974m, 1678s, 1598w, 1449m, 1178m, 1081m, 997m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.01–7.94 (m, 2H), 7.51–7.45 (m, 1H), 7.43–7.35 (m, 2H), 3.72 (br.s, 1H), 2.79–2.73 (m, 1H), 2.52–2.47 (br, 1H), 2.44 (br.s, 1H), 2.43–2.35 (m, 1H), 2.14 (d, *J* = 4.7 Hz, 1H), 1.79–1.70 (m, 2H), 1.69–1.60 (m, 1H), 1.34 (d, *J* = 5.9 Hz, 3H), 1.32–1.29 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 200.6, 136.3, 132.9, 129.5 (dd, *J* = 261.7, 253.7 Hz), 128.7, 128.7, 128.5, 128.5, 79.1 (dd, *J* = 25.9, 20.4 Hz), 52.6 (d, *J* = 4.1 Hz), 50.2, 46.4 (dd, *J* = 28.4, 21.5 Hz), 40.9 (d, *J* = 5.8 Hz), 40.7, 36.3, 31.7 (dd, *J* = 7.9, 4.2 Hz), 25.4 (d, *J* = 12.2 Hz); ¹⁹F NMR (376 MHz, CDCl₃): δ -106.6 (d, *J* = 233.9 Hz, 1F), -96.1 (dd, *J* = 233.9, 12.0 Hz, 1F); MS: *m/z* (% relative intensity) 292 (M⁺, 31), 275 (7), 105 (100), 77 (67); HRMS (ESI-TOF) calcd for C₁₇H₁₈F₂O₂Na [M + Na]⁺ 315.1173, found 315.1172.

(6*R**,6*aS**)-6-Fluoro-6-methyl-2,2-diphenyloctahydro-2*H*-3,5-methanopentaleno[1,6-*bc*]furan-6*a*-ol (**16a**). Mp 175–176 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3583s, 3406br, 2969s, 2877m, 1598w, 1493s, 1449s, 1382s, 1268m, 1144m, 1048m, 939m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.53–7.48 (m, 2H), 7.47–7.41 (m, 2H), 7.23–7.15 (m, 4H), 7.12–7.03 (m, 2H), 3.65–3.58 (m, 1H), 2.59–2.51 (m, 1H), 2.44–2.37 (m, 1H), 2.14 (s, 1H), 2.12–2.00 (m, 3H), 1.53–1.44 (m, 1H), 1.43–1.38 (m, 1H), 1.34 (d, *J* = 23.1 Hz, 3H), 1.11–1.01 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 147.4, 144.4, 128.6, 128.6, 128.0, 128.0, 127.1, 126.2, 125.6, 125.6, 125.5, 125.5, 111.9 (d, *J* = 14.9 Hz), 100.6 (d, *J* = 195.7 Hz), 90.0, 56.9, 55.7 (d, *J* = 2.1 Hz), 48.5 (d, *J* = 20.0 Hz), 42.4 (d, *J* = 6.0 Hz), 40.7, 38.7, 27.0, 22.0 (d, *J* = 27.1 Hz); ¹⁹F NMR (376 MHz, CDCl₃): δ -163.7 (q, *J* = 22.9 Hz, 1F, CF); MS: *m/z* (% relative intensity) 350 (M⁺, 12), 331 (5), 273 (69), 202 (23), 191 (62), 179 (15), 167 (100), 105 (18), 77 (21); HRMS (ESI-TOF) calcd for C₂₃H₂₃FO₂Na [M + Na]⁺ 373.1580, found 373.1586.

Synthesis of gem-Difluoromethylenated Polycyclic Cage Compounds 13a, 15a, and 17a from 9h. According to the procedure for the synthesis of **12a**, **14a**, and **16a**, the reaction of **9h** (107 mg, 0.5 mmol) with phenylmagnesium chloride (2.0 M in THF, 1.25 mL, 2.5 mmol) at 0 °C followed by heating at reflux gave **13a** (56 mg, 31%), **15a** (55 mg, 38%), and **17a** (37 mg, 21%), each as a white

solid after preparative thin-layer chromatography (SiO₂, 80% CH₂Cl₂/hexanes).

(7*aS**)-7,7-Difluoro-2,2-diphenyldecahydro-3,6-methanoindeno[1,7-*bc*]furan (**13a**). Mp 183–184 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 2949s, 2871w, 1492w, 1449w, 1368m, 1153m, 1094m, 1068s cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.51–7.44 (m, 2H), 7.42–7.35 (m, 2H), 7.25–7.15 (m, 4H), 7.14–7.03 (m, 2H), 4.21 (ddd, *J* = 13.1, 7.2, 1.2 Hz, 1H), 3.04–2.97 (m, 1H), 2.73–2.64 (m, 1H), 2.09–2.00 (m, 1H), 1.97–1.91 (m, 1H), 1.90–1.82 (m, 1H), 1.74–1.47 (m, 3H), 1.40–1.29 (m, 2H), 1.20–1.09 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 146.0, 143.4, 128.5, 128.5, 128.1, 128.1, 127.8 (dd, *J* = 264.3, 241.9 Hz), 127.0, 126.4, 125.6, 125.6, 125.5, 125.5, 92.8, 82.2 (dd, *J* = 37.5, 17.5 Hz), 50.3, 46.0, 41.3 (dd, *J* = 21.4, 21.4 Hz), 29.8 (d, *J* = 6.0 Hz), 27.9, 24.3, 23.8 (d, *J* = 6.6 Hz), 18.0; ¹⁹F NMR (376 MHz, CDCl₃): δ -124.7 (d, *J* = 231.6 Hz, 1F), -104.7 (dt, *J* = 231.6, 9.7 Hz, 1F); MS: *m/z* (% relative intensity) 352 (M⁺, 13), 351 (14), 275 (100), 182 (4), 181 (12), 77 (18); HRMS (ESI-TOF) calcd for C₂₃H₂₂F₂O₂Na [M + Na]⁺ 375.1536, found 375.1524.

((3*S**,4*R**)-2,2-Difluoro-3-hydroxyoctahydro-1*H*-1,5-methanoindeno-4-yl)(phenyl)methanone (**15a**). Mp 111–112 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3608m, 3447br, 2951s, 2875m, 1678s, 1598m, 1448m, 1346w, 1172m, 1022m, 926m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.88–7.80 (m, 2H), 7.48–7.41 (m, 1H), 7.40–7.30 (m, 2H), 4.18 (dd, *J* = 21.9, 6.6 Hz, 1H), 3.92 (s, 1H), 3.04 (br.s, 1H), 2.90–2.57 (br, 1H), 2.28–2.15 (m, 1H), 1.99–1.88 (m, 2H), 1.82 (br.s, 1H), 1.77–1.65 (m, 1H), 1.60–1.46 (m, 2H), 1.29–1.16 (m, 1H), 1.15–1.04 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 202.6, 136.6, 132.9, 128.3 (dd, *J* = 261.5, 250.2 Hz), 128.6, 128.6, 128.4, 128.4, 75.9 (dd, *J* = 32.0, 20.0 Hz), 42.7 (dd, *J* = 27.0, 20.0 Hz), 41.9, 38.9 (d, *J* = 8.0 Hz), 28.7 (d, *J* = 6.0 Hz), 27.4, 26.6 (dd, *J* = 7.0, 7.0 Hz), 21.7, 17.3; ¹⁹F NMR (376 MHz, CDCl₃): δ -116.6 (d, *J* = 232.9 Hz, 1F), -90.4 (d, *J* = 232.9, 14.1 Hz, 1F); MS: *m/z* (% relative intensity) 292 (M⁺, 3), 290 (93), 289 (100), 273 (41), 254 (7), 211 (8), 187 (15), 161 (10), 105 (60); HRMS (ESI-TOF) calcd for C₁₇H₁₈F₂O₂Na [M + Na]⁺ 315.1173, found 315.1164.

(7*R**,7*aS**)-7-Fluoro-2,2-diphenyldecahydro-3,6-methanoindeno[1,7-*bc*]furan-7*a*-ol (**17a**). Mp 208–209 °C (CH₂Cl₂/hexanes); IR (CHCl₃) 3579m, 3363br, 2947s, 2870w, 1493m, 1448m, 1311w, 1070s, 1031m, 991m cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.58–7.52 (m, 2H), 7.41–7.33 (m, 2H), 7.28–7.22 (m, 2H), 7.21–7.11 (m, 3H), 7.10–7.03 (m, 1H), 4.62 (dd, *J* = 53.4, 5.4 Hz, 1H), 3.17 (dd, *J* = 8.1, 0.9 Hz, 1H), 2.46–2.40 (m, 1H), 2.26 (s, 1H), 2.22–2.15 (m, 1H), 2.09–2.01 (m, 1H), 1.87–1.81 (m, 1H), 1.71–1.55 (m, 2H), 1.54–1.35 (m, 2H), 1.22–1.15 (br, 1H), 1.04–0.94 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 146.8, 143.5, 128.7, 128.7, 128.1, 128.1, 127.3, 126.3, 126.1, 126.1, 125.5, 125.5, 111.4 (d, *J* = 13.4 Hz), 96.8 (d, *J* = 198.5 Hz), 92.0, 53.8, 50.7, 38.2 (d, *J* = 17.4 Hz), 28.2, 27.9 (d, *J* = 8.4 Hz), 24.2, 22.2 (d, *J* = 3.8 Hz), 18.5; ¹⁹F NMR (376 MHz, CDCl₃): δ -210.8 (d, *J* = 50.4 Hz, 1F, CF); MS: *m/z* (% relative intensity) 350 (M⁺, 25), 330 (32), 273 (100), 256 (6), 106 (28), 105 (14), 77 (14); HRMS (ESI-TOF) calcd for C₂₃H₂₃FO₂Na [M + Na]⁺ 373.1580, found 373.1577.

■ ASSOCIATED CONTENT

● Supporting Information

Spectroscopic data of all compounds (copies of ¹H, ¹³C, and ¹⁹F NMR), NOE spectra of **7h** and **7h'**, NOESY spectra of **12a**–**15a**, and CIF data for single-crystal X-ray analyses of compounds **4** (CCDC 1029662), **4A** (CCDC 1029663), **11a** (CCDC 1029664), and **17a** (CCDC 1029665). This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: (+)-66-2-2015158. Fax: (+)-66-2-6445126. E-mail: manat.poh@mahidol.ac.th.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We acknowledge financial support from the Thailand Research Fund (BRGS380019), the Office of the Higher Education Commission and Mahidol University under the National Research Universities Initiative, and the Center of Excellence for Innovation in Chemistry (PERCH-CIC).

REFERENCES

- (1) (a) Hiyama, T., Ed. *Organofluorine Compounds, Chemistry and Application*; Springer: New York, 2000. (b) Shimizu, M.; Hiyama, T. *Angew. Chem., Int. Ed.* **2005**, *44*, 214–231. and references cited. (c) Welch, J. T., Ed. *Selective Fluorination in Organic and Bioorganic Chemistry*; American Chemical Society: Washington, DC, 1991. (d) Fried, J.; Mitra, D. M.; Nagarajan, M.; Mehrotra, M. M. *J. Med. Chem.* **1980**, *23*, 234–237. (e) Nakano, T.; Makino, M.; Morizawa, Y.; Matsumura, Y. *Angew. Chem., Int. Ed.* **1996**, *35*, 1019–1021. (f) Chang, C.-S.; Negishi, M.; Nakano, T.; Morizawa, Y.; Matsumura, Y.; Ichikawa, A. *Prostaglandins* **1997**, *53*, 83–90. (g) Hagmann, W. K. *J. Med. Chem.* **2008**, *51*, 4359–4369. (h) Ojima, I. *Fluorine in Medicinal Chemistry and Chemical Biology*; Blackwell: Oxford, 2009. (i) O'Hagan, D. *J. Fluorine Chem.* **2010**, *131*, 1071–1081. (j) O'Hagan, D. *Chem. Soc. Rev.* **2008**, *37*, 308–319. (k) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320–330. (l) *Giornal F.*; Pazenok, S.; Rodefled, L.; Lui, N.; Vors, J.-P.; Leroux, F. R. *J. Fluorine Chem.* **2013**, *152*, 2–11.
- (2) For recent reviews and synthetic methods for syntheses of organofluorines, see: (a) Hafner, A.; Jung, N.; Bräse, S. *Synthesis* **2014**, *46*, 1440–1447. (b) Xu, J.; Liu, X.; Fu, Y. *Tetrahedron Lett.* **2014**, *55*, 585–594. (c) Konno, T. *Synlett* **2014**, *25*, 1350–1370. (d) Ni, C.; Hu, J. *Synthesis* **2014**, *46*, 842–863. (e) Lin, A.; Huehls, C. B.; Yang, J. *Org. Chem. Front.* **2014**, *1*, 434–438. (f) Ma, J.-A.; Li, S. *Org. Chem. Front.* **2014**, *1*, 712–715. (g) Wang, H.; Vici, D. A. *Synlett* **2013**, *24*, 1887–1898.
- (3) For selected recent examples for difluoromethylation, see: (a) Zemtsov, A. A.; Kondratyev, N. S.; Levin, V. V.; Struchkova, M. I.; Dilman, A. D. *J. Org. Chem.* **2014**, *79*, 818–822. (b) Zhang, B.; Studer, A. *Org. Lett.* **2014**, *16*, 1216–1219. (c) Salomon, P.; Zard, S. Z. *Org. Lett.* **2014**, *16*, 1482–1485. (d) Min, Q.-Q.; Yin, Z.; Feng, Z.; Guo, W.-H.; Zhang, X. *J. Am. Chem. Soc.* **2014**, *136*, 1230–1233. (e) Munemori, D.; Narita, K.; Nokami, T.; Itoh, T. *Org. Lett.* **2014**, *16*, 2638–2641. (f) Gao, B.; Zhao, Y.; Hu, M.; Ni, C.; Hu, J. *Chem.—Eur. J.* **2014**, *20*, 2750–2754. (g) Prakash, G. K. S.; Krishnamoorthy, S.; Ganesh, S. K.; Kulkarni, A.; Haiges, R.; Olah, G. A. *Org. Lett.* **2014**, *16*, 54–57. (h) Feng, Z.; Min, Q.-Q.; Xiao, Y.-L.; Zhang, B.; Zhang, X. *Angew. Chem., Int. Ed.* **2014**, *53*, 1669–1673. (i) Lee, G. M.; Harrison, D. J.; Korobkov, I.; Baker, R. T. *Chem. Commun.* **2014**, *50*, 1128–1130. (j) Li, W.; Zhu, X.; Mao, H.; Tang, Z.; Cheng, Y.; Zhu, C. *Chem. Commun.* **2014**, *50*, 7521–7523. (k) Ma, G.; Wan, W.; Hu, Q.; Jiang, H.; Wang, J.; Zhu, S.; Hao, J. *Chem. Commun.* **2014**, *50*, 7527–7530. (l) Hu, M.; He, Z.; Gao, B.; Li, L.; Ni, C.; Hu, J. *J. Am. Chem. Soc.* **2013**, *135*, 17302–17305. (m) Prakash, G. K. S.; Ni, C.; Wang, F.; Zhang, Z.; Haiges, R.; Olah, G. A. *Angew. Chem., Int. Ed.* **2013**, *52*, 10835–10839. (n) Zhou, Q.; Ruffoni, A.; Gianatassio, R.; Fujiwara, Y.; Sella, E.; Shabat, D.; Barran, P. S. *Angew. Chem., Int. Ed.* **2013**, *52*, 3949–3952. (o) Chia, P. W.; Bello, D.; Slawin, A. M. Z.; Ó Hagan, D. *Chem. Commun.* **2013**, *49*, 2189–2191. (p) Thomason, C. S.; Dolbier, W. R., Jr. *J. Org. Chem.* **2013**, *78*, 8904–8908. (q) Li, L.; Wang, F.; Ni, C.; Hu, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 12390–12394. (r) Zhao, Y.; Huang, W.; Zheng, J.; Hu, J. *Org. Lett.* **2011**, *13*, 5342–5345. (s) Fourrière, G.; Hijfte, N. V.; Lalot, J.; Dutech, G.; Fragnet, B.; Coadou, G.; Quirion, J.-C.; Leclerc, E. *Tetrahedron* **2010**, *66*, 3963–3972. (t) Yue, X.; Zhang, X.; Qing, F.-L. *Org. Lett.* **2009**, *11*, 73–76. (u) Diab, S. A.; Sene, A.; Pfund, E.; Lequeux, T. *Org. Lett.* **2008**, *10*, 3895–3898. (v) Huguenot, F.; Billac, A.; Brigand, T.; Portella, C. *J. Org. Chem.* **2008**, *73*, 2564–2569. (w) Uneyama, K. *J. Fluorine Chem.* **2008**, *129*, 550–576. (x) Verniest, G.; Surmont, R.; Hende, E. V.; Deweire, A.; Deroose, F.; Thuring, J. W.; De Kimpe, N. *J. Org. Chem.* **2008**, *73*, 5458–5461. (y) De Kimpe, N.; Van Brabant, W. *Synlett* **2006**, 2039–2042.
- (4) (a) Prakash, G. K. S.; Hu, J.; Olah, G. A. *J. Org. Chem.* **2003**, *68*, 4457–4463. (b) Prakash, G. K. S.; Hu, J.; Wang, Y.; Olah, G. A. *J. Fluorine Chem.* **2005**, *126*, 529–534. (c) Mizuta, S.; Shibata, N.; Ogawa, S.; Fujimoto, H.; Nakamura, S.; Toru, T. *Chem. Commun.* **2006**, 2575–2577.
- (5) Thaharn, W.; Bootwicha, T.; Soorukram, D.; Kuhakarn, C.; Prabpai, S.; Kongsaree, P.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *J. Org. Chem.* **2012**, *77*, 8465–8479.
- (6) Bootwicha, T.; Panichakul, C.; Kuhakarn, C.; Prabpai, S.; Kongsaree, P.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *J. Org. Chem.* **2009**, *74*, 3798–3805.
- (7) Chatupheeraphat, A.; Soorukram, D.; Kuhakarn, C.; Tuchinda, P.; Reutrakul, V.; Pakawatchai, C.; Saithong, S.; Pohmakotr, M. *Eur. J. Org. Chem.* **2013**, 6844–6858.
- (8) Punirun, T.; Peewasan, K.; Kuhakarn, C.; Soorukram, D.; Tuchinda, P.; Reutrakul, V.; Kongsaree, P.; Prabpai, S.; Pohmakotr, M. *Org. Lett.* **2012**, *14*, 1820–1823.
- (9) Peewasan, K.; Kuhakarn, C.; Soorukram, D.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *J. Fluorine Chem.* **2012**, *135*, 367–372.
- (10) Pohmakotr, M.; Boonkitpattarakul, K.; Ieawsuwan, W.; Jarussophon, S.; Duangdee, N.; Tuchinda, P.; Reutrakul, V. *Tetrahedron* **2006**, *62*, 5973–5985.
- (11) Boonkitpattarakul, K.; Soorukram, D.; Kuhakarn, C.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *J. Fluorine Chem.* **2011**, *132*, 987–990.
- (12) Pharikronburee, V.; Punirun, T.; Soorukram, D.; Kuhakarn, C.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *Org. Biomol. Chem.* **2013**, *11*, 2022–2033.
- (13) Thaharn, W.; Soorukram, D.; Kuhakarn, C.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *Angew. Chem., Int. Ed.* **2014**, *53*, 2212–2215.
- (14) (a) Struble, M. D.; Strull, J.; Patel, K.; Siegel, M. A.; Lectka, T. *J. Org. Chem.* **2014**, *79*, 1–6. (b) Dolbier, W. R., Jr.; Zhai, Y.-A.; Battiste, M. A.; Ghiviriga, I. *J. Org. Chem.* **2005**, *70*, 10336–10341.
- (15) For reviews, see: (a) Eaton, P. E. *Angew. Chem., Int. Ed. Engl.* **1992**, *31*, 1421–1436. (b) Griffin, G. W.; Marchand, A. P. *Chem. Rev.* **1989**, *89*, 997–1010. (c) Marchand, A. P. *Chem. Rev.* **1989**, *89*, 1011–1033. (d) Paquette, L. A. *Chem. Rev.* **1989**, *89*, 1051–1065. (e) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. *Chem. Rev.* **2014**, *114*, 2432–2506.
- (16) For some recent syntheses of polycyclic cage compounds and biological activities of some compounds, see: (a) Smith, M. W.; Snyder, S. A. *J. Am. Chem. Soc.* **2013**, *135*, 12964–12967. (b) Tomilov, Y. V.; Platonov, D. N.; Shulishov, E. V.; Okonnishnikova, G. P. *Tetrahedron* **2013**, *69*, 6855–6860. (c) Mott, B. T.; Tripathi, A.; Siegler, M. A.; Moor, C. D.; Sullivan, D. J.; Posner, G. H. *J. Med. Chem.* **2013**, *56*, 2630–2641. (d) Guney, T.; Kraus, G. A. *Org. Lett.* **2013**, *15*, 613–615. (e) Banister, S. D.; Manoli, M.; Doddareddy, M. R.; Hibbs, D. E.; Kassiou, M. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 6053–6058. (f) Torres, E.; Duque, M. D.; Lopez-Querol, M.; Taylor, M. C.; Naesens, L.; Ma, C.; Pinto, L. H.; Sureda, F. X.; Kelly, J. M.; Vazquez, S. *Bioorg. Med. Chem.* **2012**, *20*, 942–948. (g) Lin, H.-C.; Wu, H.-J. *J. Chin. Chem. Soc. (Weinheim, Ger.)* **2009**, *56*, 1072–1077. (h) Duque, M. D.; Camps, P.; Torres, E.; Valverde, E.; Sureda, F. X.; Lopez-Querol, M.; Camins, A.; Prathalingam, S. R.; Kelly, J. M.; Vazquez, S. *Bioorg. Med. Chem.* **2010**, *18*, 46–57. (i) Gharpure, S. J.; Porwal, S. K. *Tetrahedron Lett.* **2009**, *50*, 7162–7165. (j) Pillekamp, M.; Alachraf, W.; Oppel, I. M.; Dyker, G. *J. Org. Chem.* **2009**, *74*, 8355–8358. (k) Zimmer, R.; Taszarek, M.; Schefzig, L.; Reissig, H.-U. *Synlett* **2008**, 2046–2050. (l) Gharpure, S. J.; Porwal, S. K. *Synlett* **2008**, 242–246. (m) Xu, W.; Dolbier, W. R., Jr.; Salazar, J. *J. Org. Chem.* **2008**, *73*, 3535–3538. (n) James, B.; Viji, S.; Mathew, S.; Nair, M. S.; Lakshmanan, D.; Kumar, R. A. *Tetrahedron Lett.* **2007**, *48*, 6204–6208. (o) James, B.; Suresh, E.; Nair, M. S. *Tetrahedron Lett.* **2007**, *48*, 6059–6063. (p) Ye, Q.; Komarov, I. V.; Kirby, A. J.; Jones, M., Jr. *J. Org. Chem.* **2002**, *67*, 9288–9294. (q) Carreño, M. C.; Luzón, C. G.;

- Ribagorda, M. *Chem.—Eur. J.* **2002**, *8*, 208–216. (r) Giomi, D.; Nesi, R.; Turchi, S.; Mura, E. *J. Org. Chem.* **2000**, *65*, 360–364. (s) Wu, H.-J.; Chao, C.-S.; Lin, C.-C. *J. Org. Chem.* **1998**, *63*, 7687–7693. (t) Wu, H.-J.; Tsai, S.-H.; Chern, J.-H.; Lin, H.-C. *J. Org. Chem.* **1997**, *62*, 6367–6373. (u) Wu, H.-J.; Chern, J.-H. *J. Org. Chem.* **1997**, *62*, 3208–3214. (v) Mehta, G.; Srikrishna, A. *Chem. Rev.* **1997**, *97*, 671–719. (w) Lin, R.-L.; Wu, C.-Y.; Chern, J.-H.; Wu, H.-J. *J. Chinese Chem. Soc.* **1996**, *43*, 289–295. (x) Wu, H.-J.; Lin, C.-C. *J. Org. Chem.* **1995**, *60*, 7558–7566. (y) Wu, H.-J.; Huang, F. J.; Lin, C.-C. *J. Chem. Soc., Chem. Commun.* **1991**, 770–771. (z) Marchand, A. P. *Synlett* **1991**, 73–79.
- (17) (a) Masusai, C.; Soorukram, D.; Kuhakarn, C.; Tuchinda, P.; Pakawatchai, C.; Saithong, S.; Reutrakul, V.; Pohmakotr, M. *Org. Biomol. Chem.* **2013**, *11*, 6650–6658. (b) Masusai, C.; Soorukram, D.; Kuhakarn, C.; Tuchinda, P.; Reutrakul, V.; Pohmakotr, M. *J. Fluorine Chem.* **2013**, *154*, 37–42.
- (18) Pohmakotr, M.; Thamapipol, S.; Tuchinda, P.; Reutrakul, V. *Tetrahedron* **2007**, *63*, 1806–1820.
- (19) For reviews on radical cyclization, see: (a) Zard, S. Z. *Radical Reactions in Organic Synthesis*; Oxford University Press: Oxford, 2003. (b) Curran, D. P.; Porter, N. A.; Giese, B. *Stereochemistry of Radical Reactions*; VCH: Weinheim, 1996. (c) Motherwell, W. B.; Crich, D. *Free Radical Chain Reactions in Organic Synthesis*; Academic Press: London, 1991. (d) McCarroll, A. J.; Walton, J. C. *Angew. Chem., Int. Ed.* **2001**, *40*, 2224–2248.